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INTRODUCTION

Underlying the cytoplasmic surface of the human erythrocyte membrane is a
dense, two-dimensional network of spectrin and other proteins that provide support
to the lipid bilayer and afford the red cell its unique flexibility (Bennett & Gilligan,
1993).

As part of the erythrocyte skeleton spectrin plays a critical role in

maintaining the architecture of the red cell membrane by aiding in the restriction of
the lateral mobility of integral membrane proteins. For these reasons the erythrocyte
skeleton is necessary for the survival of the erythrocytes as they travel through the
high shear environment of the vascular system (Lux, 1979; Elgsaeter & Mikkelson,
1991).

Spectrin was first isolated from the low-ionic strength extracts of the

erythrocyte membrane (Marchesi & Steers, 1968; Clarke, 1971; Fairbanks et al.,
1971). Hemoglobin-free erythrocyte membranes are nicknamed "ghosts" as a result
of their white color after hemoglobin removal.

At this point a skeleton (largely

comprised of spectrin) remains, thus the name "spectrin" originated from the
expression "ghosts", i.e. specter.
The basic unit of spectrin is a heterodimer, consisting of two distinct
spectrins, a-spectrin (280 kDa) and J3-spectrin (246 kDa), associated m an
antiparallel manner (Speicher et al., 1982).

Spectrin dimers can associate in a

"head-to-head" manner to form tetramers (Kam et al., 1977; Ungewickell &
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Gratzer, 1978). It has been determined that the "head-to-head" assembly consists
of an association between the N-terminal end of the a-spectrin and the C-terminal
end of the f3-spectrin (Morris & Ralston, 1989; DeSilva et al., 1992; Speicher et

al., 1993).

The association of the spectrin heterodimer to form tetramers is

essential to the formation of the erythrocyte skeleton and thus to the integrity of
the membrane. Many hereditary hemolytic anemias involve spectrin mutations
which destabilize tetramer formation (Delaunay & Dhermy, 1993; Marchesi,
1989).
Several other proteins, such as dystrophin, alpha-actinin, fibrin, etc. Share
many properties similar to those of erythrocyte spectrin and are grouped as the
spectrin super-family (Bennett & Gilligan, 1993).

Thus it is important to

understand the structural properties of spectrin.
Amino acid (Speicher, et al., 1983) and cDNA (Sahr et al., 1990;
Winkelmann et al., 1990) sequence analyses of human erythrocyte spectrin reveal
that most parts of both subunits consist of homologous sequence motifs. Each
motif consists of about 106-amino-acids in length. There are 22 sequence motifs
in tandem in the a-spectrin and 17 sequence motifs in the f3-spectrin.

These

sequence motifs have been suggested to fold into stable structural domains,
consisting mostly of coiled-coils of triple helices (Parry & Cohen, 1991; Speicher

et al., 1993). Other members of the spectrin super-family also consist of similar
sequence motifs.
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This dissertation consisted of three parts. The objective of the first part
was to identify the boundaries {phasing) of the suggested 106-amino-acid
sequence motif in spectrin. We found that the first amino acid residue of the first
structural domain of a-spectrin was 52 (Ser) (Lusitani el al., 1994). The second
part of this dissertation addressed the issue of finding a spectrin fragment which
was an appropriate model for the spectrin dimer. In this second part, the amide I
peak frequencies and helical content obtained by Fourier transform infrared along
with resistance to proteolytic digestion were used to this end. It was found that
while the single-domain peptides exhibited substantial helical content and were
protease resistant structures, the multiple-domain peptides were both more
helical and more resistant to proteolytic digestion. When all of my results on
FflR, proteolytic digestion, CD and fluorescence were considered it was found

that the multiple-domain peptides more faithfully represented the features
exhibited by the spectrin dimer (Menhart et al., 1996). The third part of this
dissertation held the same objective as the second, but focused on finding an
appropriate model to the ionic strength mediated differences found in the spectrin
dimer.

Again it was found that the multiple-domain peptides more closely

embodied the features found for the spectrin dimer.

PART I

CHAPTER I

REVIEW
1.1

Phasing Problem

In the first part of this dissertation, we began with the objective of
determining the proper phasing of the canonical 106-amino-acid sequence
motifs.

This is non-obvious since both the a- and f3-spectrin polypeptides

contain many such motifs in tandem without any obvious delimiting structures.
For

example,

when

regarding

the

repetitive

sequence

of

letters

ABCDABDABCDABCD it is necessary to know what four letter segment of
sequence forms a structural domain, i.e. is the structure ABCD, BCDA, CDAB
or DABC.

Additionally, the onset of the repeating sequence motif could not

be assumed to correspond with the start of a protein structural domain since
both a- and f3-spectrin contain non-integral numbers of such repeats.

This

implies the existence of fractional sequence motifs, which might occur at any
point in the sequence. In order to attack this problem, we began with the
hypothesis that a spectrin fragment that contains a complete 106-amino-acid
sequence motif, in the proper phase, will also contain a stable, well-folded
structural domain (Speicher & Marchesi, 1984). Since proteolytic sensitivity
5
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has been correlated to the flexibility (Fontana et al., 1986) and accessibility
(Novotny & Bruccoleri, 1987) of peptide structures, this well folded fragment
will be less susceptible to proteolytic digestion than fragments that have
incorrectly phased reading frames and thus are not well-folded. If in addition to
the complete structural domain, the peptide contains additional amino acids
residues, the region containing the "extra" amino acid residues is likely to be
disordered and thus very sensitive to protease digestion. We chose elastase as
the protease to conduct these experiments because it is relatively nonspecific,
cleaving at the C-terminal side of the small nonpolar amino acid residues G, A,
V, L, I and S (Ardelt, 1974).

Using recombinant peptides and proteolytic

digestion we identified the first sequence motif of a-spectrin as residues 52-156
(Lusitani et al., 1994) (Appendix I).

PART II

CHAPTER II

REVIEW
2.1

Whole Domains

In the second part of this dissertation, we began with the objective of
finding a suitable peptide model for the spectrin dimer. In this work we used
Fourier transform (FT) infrared (IR) to investigate the secondary structure and
hydrogen-bonding strength of the correctly phased recombinant spectrin
peptides Spa52-156 (a general abbreviation where Spa represents a-spectrin
and 52-156 is the amino acid residue numbers in a-spectrin), Spa157-262,
Spa263-368, Spa52-262, Spa157-368 and Spa52-368 in comparison with
native spectrin dimer. IR spectroscopy is sensitive to the interactions of the
protein backbone as represented by C=O stretching (1600-1700 cm·1, amide I
region) and N-H bending (1500-1600 cm· 1, amide II region). Differences in the
strength of the hydrogen-bonding of different secondary structures as well as
within a secondary structure are represented as changes in the frequencies of
the previously mentioned IR absorbances (Dousseau et al., 1989). For proteins
with high a-helical content under similar experimental conditions it has been
shown that low amide I band frequencies correspond to a large fraction of
ordered helix versus disordered helix and thus a long helical length. This
8
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ordered helix versus disordered helix and thus a long helical length. This
frequency shift has been correlated to the difference in hydrogen bonding of
amide groups at the end of helical segments (disordered helix) compared to
those in the center (ordered helix) (Van Wart & Scheraga, 1978). The use of
both FTIR and circular dichroism (CD) methods leads to more thorough
predictions of both 13-sheet (Sarver & Kreuger, 1991) and a-helix. We found
that the multiple-domain peptides were more faithful in representing the
hydrogen-bonding strength and helicity found for the spectrin dimer. We also
used protease digestion to compare the stability of the peptides. It was found
that the single-domain peptides (Spa52-156, Spa157-262 and Spa263-368)
form a self-contained and protease resistant structure. However, these peptides
were least resistant to digestion, followed by the peptides with two domains
(Spa52-262 and Spa157-368) and finally the three domain peptide (Spa52368). The paper describing this work has been published (Menhart et al., 1996)
(Appendix II).

PART III

CHAPTER III

REVIEW

3 .1

Salt Effect

The erythrocyte is subjected to much stress as it travels the circulatory
system and must elastically deform in order to maintain the cells integrity. The
source of erythrocyte elasticity, though still not directly known, has been
generally attributed to the membrane skeleton and, more specifically to spectrin.
Spectrin is a protein with unique elasticity (Elgsaeter, 1978) and flexibility
(Fung & Johnson, 1983). The elasticity and flexibility of spectrin may have
physiological significance in that they may be directly related to the
deformability and elasticity of the erythrocyte itself. It has been suggested that
the elasticity of spectrin is entropically driven (Vertessy & Steck, 1989).
Utilizing electron micrographs it has been found that buffer with ionic
strengths lower than physiological amounts produce an artificially elongated
spectrin molecule when studied as part of the membrane skeletal complex (Liu

et al., 1987; Shen et al., 1986; Byers & Branton, 1985) and when studied
independently as a tetramer (Shotton et al., 1979). The extracted membrane
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skeleton, and thus spectrin by association, has been found to shrink m
increasing ionic strengths (Svoboda et al., 1992). Partially extended skeletons
have been studied by using a 2rnM sodium phosphate and 0.05 rnM MgCh
buffer (McGough & Josephs, 1990).

This study revealed that a- and

P-

spectrin of the spectrin dimer twist around one another forming a two-start
helix with twofold rotational symmetry in which both the pitch and diameter are
variable and coupled (McGough & Josephs, 1990).

The decreasing size in

higher ionic strength buffers has been attributed to classical charge screening
effects (Vertessy & Steck, 1989).
Conformational changes in spectrin upon varying ionic strengths have
been used as a method of modeling the changes in spectrin's conformation that
occur in vivo and are responsible for its unique flexibility. For example, it has
been shown that the Stokes radius of spectrin is larger in low ionic strength
buffer than in high ionic strength buffer (LaBrake, 1993). The same trend in
Stokes radius was also seen for spectrin peptides encompassing two or three
structural domains (Xu, 1994).

In addition, using optical rotary dispersion

(ORD) and calorimetry techniques Ralston & Dunbar (1979) detected broader
thermal denaturation transitions for spectrin in 5 rnM phosphate with no NaCl
than for spectrin in 5 rnM phosphate with 100 rnM NaCl. It has similarly been
seen by proton NMR that a wider unfolding range is found for the thermal
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denaturation of spectrin dimer in 1.5 mM phosphate buffer with no NaCl versus
spectrin in 1. 5 mM phosphate buffer with 150 mM NaCl (Begg et al., 1994).
In this part of the dissertation, we have shown that peptides with more
than one structural domain expressed in tandem more accurately represented
the structural and thermal unfolding properties of the spectrin dimer in respect
to ionic strength differences. In the multiple-domain peptides as well as in the
spectrin dimer we found that the temperature values for 50 % unfolding (Tm)
were identical within experimental error as determined by thermal denaturation
monitored by both fluorescence and CD.

We found a broader range of

unfolding for spectrin dimer in 5 mM phosphate buffer at pH7.4 with no NaCl
(5P7.4) than in 5 mM phosphate buffer with 150 mM NaCl (PBS7.4) and have
shown, that for this feature also, the multiple-domain peptides more closely
replicated the spectrin dimer. From this conclusion, the interacting regions of
the domains, i.e. the regions where the C-terminal end of the first domain
interacting with the N-terminal end of the next, are implicated as the source of
these salt induced unfolding differences. In addition we have re-addressed the
elastase digestions discussed in Part II.

We have obtained the N-terminal

sequence analysis of the most prominent bands formed from the digestion of the
multiple-domain peptides and will discuss these results in reference to the ionic
strength induced thermal unfolding differences. It was also necessary to readdress the FTIR discussed in Part II due to the recently discovered sample
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contamination problem (Mitchell, 1997) that affected the FTIR data obtained
earlier.

CHAPTER IV

MATERIALS AND METHODS

4 .1

Chemicals

All chemicals were reagent grade and were from purchased Aldrich
Chemical Company, Inc. (Milwaukee, WI), Fisher Scientific (Pittsburgh, PA),
or Sigma Chemical Company (St. Louis, MO), unless stated otherwise.
Polyvinylidene difluoride (PVDF) membranes were obtained from Applied
Biosystems (Foster City, CA); ammonium persulfate from BioRad (Richmond,
CA); and ultrapure acrylamide and N, N - Methylenebisacrylamide from
Shwarz!MannBiotech (Cambridge, MA).

4.2

Oligonucleotides and Enzymes

All oligonucleotide primers were ordered from the Biocore Facility,
University of Notre Dame (South Bend, ID). Restriction endonucleases were
purchased from Gibco BRL Life Technologies (Gaithersburg, MD) or New
England BioLabs (Beverly, MA). Elastase was ordered from Sigma (St. Louis,
MO).
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4.3

Preparation of Competent Cells

A three mL overnight growth of the E. coli cell line DH5a was
prepared in Luria broth (LB). LB was prepared by adding 1 G tryptone, 0.5 G
yeast extract and 0.5 G NaCl per 100 mL of tap water. The overnight growth
was used to inoculate 50 mL of SOC medium in a 500 mL flask. SOC medium
consisted of 1% glucose solution, 1.25 mM KCl, 5 mM NaCl, 5 mM MgCh,
0.5 mM MgS04, 10 G tryptone and 2.5 G yeast extract per liter.

The

inoculating in SOC medium was grown for 2 hours until the optical density at
600 nm was equal to 0.15 - 0.20, with a water blank, at which point it was
immediately chilled to 4 °C. The cells were transferred to a sterile 50 mL tube
and collected by centrifugation in a Sorvall RT6000B refrigerated table top
centrifuge at 2800 x g for 5 minutes at 4 °C. The supernatant was decanted and
the packed cells were resuspended with 16 mL of RF-1 solution and allowed to
sit on ice for 15 minutes. RF-1 solution contained 12 G RbCl, 9. 9 G MnCh,
2.9 G K02H2, 1.5 G CaCh and 15% glycerol per liter at pH 5.8. The cells were
again collected by centrifugation as described above and the RF-1 solution was
decanted. The cells were resuspended in 4 mL ofRF-2 solution and fast frozen
with liquid N 2 in 200 µL aliquots for storage at -80 °C.

RF-2 solution

contained 10 mM MOPS, 1.2 G RbCl, 11.0 G CaCh•4H20 and 15% glycerol.
The pH of RF-2 was adjusted to 6.8 with NaOH. Both RF-1 and RF-2 were
not autoclaved but were instead filtered through sterile filters into sterile
containers.
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4.4
4.4.1

DNA Manipulations
Oligonucleotide Purification

Further purification of the oligonucleotides was carried out usmg
Waters Oligo-Pak Synthetic Oligonucleotide Purification Columns (Millipore
Corporation, Milford, MA), following the instructions provided.
DMT protected oligonucleotides were cleaved from

Briefly, 5'

their synthesis column

overnight using a 30% ammonium hydroxide solution.

The recovered

oligonucleotides were loaded onto a preconditioned Oligo-Pak column, the
failure sequences were eluted using a 3% ammonium hydroxide solution and the
column was washed with deionized (DI) water.

Then the purified

oligonucleotides were detritylated ( dimethoxytriphenylmethyl) by washing with
2% trifluoroacetic acid (TF A) followed immediately by rinsing with DI water to
remove the excess TF A. The detritylated oligonucleotides were eluted from the
column using a 20% acetonitrile solution and then lyophilized and stored at -20

oc.
4.4.2

Polymerase Chain Reaction (PCR)

The design of the primers was described in a published paper (Menhart

et al., 1996) (Appendix II).

After the PCR reaction was carried out the

products were purified using Magic PCR Preps (Promega, Madison, WI),
following the instructions provided for purification without a vacuum manifold.
Briefly, a sample was prepared by vortexing with Direct Purification Buffer and
then adding Magic PCR Preps Resin and vortexing several more times over one
minute. Next, the sample was purified by addition of the resin mixture to a
Magic Minicolumn, washing with 80% isopropanol and drying by brief
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centrifugation at 12,000 x g. The DNA was eluted by addition of TE buffer (10
mM Tris-HCI, 5 mM EDTA at pH 7.5), waiting for 1 minute and brief
centrifuging at 12,000 x g. The DNA was stored at -20 °C.

4.4.3

DNA Digestions

Restriction enzyme digestions of plasmid and PCR product DNA were
carried out in the buffers provided by the manufacturer for each enzyme and
under the recommended conditions. All reactions were made to a total volume
of 20 µL which included 2 µL of 1Ox reaction buffer, 2 U of each restriction
enzyme, 1-3 µL of DNA (depending on the concentration) and 14-17 µL of DI
water.

The reactions were incubated at 37 °C for 3 hours, stopped and

visualized by addition of DNA loading buffer and running on 1% agarose gels
as described in section 2.4.4.

4.4.4

DNA Agarose Electrophoresis

To prepare the digest samples for electrophoresis 5 µL of DNA loading
buffer, 50% glycerol, 1% sodium dodecyl sulfate (SDS) and 200 mM
ethylenediamine tetraacetic acid (EDT A) with bromophenol blue were added to
the DNA samples. The samples were then separated on a 1% agarose gel. 1 G
of agarose was dissolved, by boiling, in 10 G of 1Ox TBE buffer (105 G Tris
base, 55 G Boric acid and 0.75 G EDTA disodium at - pH 8.3) and 90 mL DI
water. When the solution had cooled to 60 °C, 4 µL of ethidium bromide ( 10
mG/mL) was added. The mixture was stirred gently and then poured into a
horizontal gel casting tray (International Biotechnologies, New Haven, CT).
The gel was allowed to solidify before being transferred to the electrophoresis
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chamber (International Biotechnologies, New Haven, CT) filled with TBE
buffer. The entire DNA sample was loaded into a well and the electrophoresis
was run at a constant voltage of 140 V until the bands had migrated the desired
distance as monitored with a hand held ultra violet lamp (UVP, Inc. San
Gabriel, CA).

Lamda DNA samples were cleaved with either restriction

enzyme Hindlll, Mlul, or Pvull and were run in a separate well to serve as
molecular weight standards.

Upon completion of electrophoresis the DNA

bands were viewed using an ultra violet light table.

4.4.5

Digested Plasmid and Digested PCR Fragment Purification

DNA fragments were recovered from agarose gel electrophoresis by
excising the area of gel which contained the desired fragment. The section of
gel was then placed in a 0.5 mL microcentrifuge tube that had been prepared by
poking a hole in the bottom with a needle, lining the inside with glass wool and
placing the entire 0.5 mL tube into an intact 1 mL microcentrifuge tube. The
excised gel was then centrifuged at 15,000 x g (Marathon MicroA, Fisher
Scientific, Pittsburgh, PA) for a short time to elute the DNA from the agarose.
The recovered DNA was then purified following the same method described
above in section 2.4.2 for purification of PCR fragments.

4.4.6

DNA Ligation

Each ligation reaction mixture contained 4 µL of 5x ligation buffer
(provided with the enzyme), 2 units of T4 ligase, 2µL of each DNA fragment
and 5 µL of DI water.

The reactions were allowed to proceed at 15 °C

20

overnight and then the T4 ligase was inactivated at 70 °C before the DNA was
transformed.

4.4.7

DNA Transformation into Competent Cells

A 200 µL aliquot of competent cells prepared as described above in
section 2.4 were thawed on ice. Ligated DNA was added to the cells, so as it
was not over 10% of the total volume, and the cell/DNA mixture was incubated
on ice for 1.5 hours. Then the mixture was heat shocked in a 42 °C water bath
for 1.5 minutes. Next

~ 1.5

mL of SOC medium was added and the cells were

grown for 1. 5 hours, to allow expression of the antibiotic resistance gene,
before being plated onto an LB plate containing the appropriate antibiotic.
Transformants were screened for the proper DNA by identifying the presence of
plasmid DNA, purified from the transformant as described below in section
2.4.8, and then confirming the plasmids contents through selected restriction
enzyme digestions. When a correct transformant was identified it was stored as
a glycerol freeze down. An 800 µL overnight of the desired transformant was
added to 200 µL of 100% glycerol, mixed briefly, fast frozen with liquid N 2 and
stored at -80 °C.

4.4.8

Plasmid DNA Purification

To purify plasmid DNA, a 3 mL overnight growth of the cells
containing the desired plasmid was grown in LB. The next day the overnight
growth was divided into two 1. 5 mL microcentrifuge tubes and the cells were
collected by centrifugation at 15,000 x g. The supernatant was discarded and
the cells were resuspended in 200 µL of GTE buffer (50% glycerol, 25 mM Tris
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base, 10 mM EDTA at pH-7.9) with vortexing. The cells were lysed and most
of the chromosomal DNA and RNA were removed by addition of 400 µL of
0.2 MNaOH, 1% SDS and incubating on ice for 5 minutes. Next, proteins and
SDS were removed by precipitation upon addition of 4 N potassium acetate at
pH 4.6 and placement in the -20 °C freezer for 10 minutes. The precipitate was
removed by centrifugation at 15,000 x g for 5 minutes. To precipitate the DNA
the supernatant was transferred to a new tube containing 500 µL of
isopropanol, briefly mixed and allowed to sit on ice for 15 minutes. Then the
DNA was pelleted by centrifugation at 15,000 x g for 8 minutes.

The

isopropanol was discarded and the pellet was washed once with 70% ethanol.
The ethanol was poured off and the pellet was allowed to dry under vacuum for
- 2 hours. The pellet was resuspended in 12 µL of TE buffer with 100 µG/mL
RNase and stored at -20 °C.

4.5

Expression of Spectrin Fusion Proteins

An overnight culture of cells with the desired spectrin fusion protein
plasmid was diluted 20 fold into 4 L of fresh Terrific Broth (TB), in the
fermenter carboy (Labline Instruments, Rosemont, IL), with an ampicillin
(antibiotic) concentration of lOOmG/L. The TB was prepared earlier by mixing
12 G tryptone, 24 G yeast extract, 4 mL glycerol and 900 mL tap water,
followed by autoclaving. Also prepared and autoclaved was 2.31 G KH2P04
monobasic and 12.54 G K2HP04 dibasic in 100 mL DI water.

After

autoclaving the two solutions were combined to make TB. 400 µL of Antifoam
289 (Sigma Chemical Company, St. Louis, MO) was also added to the carboy.
The carboy was then placed into the constant temperature chamber (3 7° C) and

22

allowed to rotate at 300 rpm, with an air flow of 10 L/min, to allow cells to
grow to mid-log phase (optical density at 600 nm equal to 0.6-1), usually about
3 hours. At this time expression of the spectrin fusion protein was induced by
adding isopropylthiogalactosidase to a final concentration of O. lmM. Induced
cells were allowed to grow for about 3 more hours, until the OD600

=

1.5 -2.5,

before being harvested by centrifugation at 7,000 x g in a Sorvall RC-SB
refrigerated centrifuge (DuPont Company, Wilmington, DE) at 4° C.

The

supernatant was decanted and, if necessary, the packed cells were stored at -20°
C.

4.6

Purification of Fusion Proteins

Packed cells from a single growth were resuspended in 1/4 w/v of 5 mM
Na-P0 4 , 150 mM NaCl, 1% Triton X-100 at pH 7.4. The resuspended cells
were then lysed by mild sonication on ice and then centrifuged at 10,000 x g for
5 minutes at 4 °C. The fusion proteins, glutathione - S - transferase (GST) thrombin cleavage site - spectrin peptides, were separated from other lysate
proteins via passage over a glutathione (GSH) affinity column (GSH Sepharose 4B resin from Pharmacia).

The column was washed with 10

volumes of 5 mM phosphate, 150 mM sodium chloride at pH 7.4 (PBS7.4)
followed by fusion protein elution with 50 mM Tris and 5 mM GSH at pH 8.

4. 7

Thrombin Cleavage of Fusion Proteins

Dithiothreitol (DTT) was added to the purified fusion protein to a
concentration of 1 mM to facilitate removal of GSH. Without the addition of
DTT the samples were found to be contaminated with GSH despite thorough

23

dialysis.

The fusion protein was then dialized in Tris 25 mM pH 8.6 and

cleaved with 200 U of thrombin per µmol of fusion protein. The reaction was
carried out at 37° C, with agitation, for 1 hour.

4.8

Purification of Cleaved Peptides

The thrombin cleaved protein was passed over the GSH affinity column
to separate spectrin peptide from free GST and any uncleaved fusion protein.
The spectrin peptide was eluted with PBS7.4. When needed the peptides were
further purified by either fast protein liquid chromatography (FPLC), with a
Mono Q column (Pharmacia, Piscataway, NJ), using 40 mM Tris at pH 7.5 and
a sodium chloride gradient, or size exclusion chromatoghraphy (G-75), using
PBS7.4. Purified spectrin peptides were dialized into 5 mM phosphate buffer at
pH 7.4 (5P7.4) and concentrated to 1-5 mG/mL before being stored at -80 °C.
For studies in PBS7.4, 3M NaCl was diluted 20x into a sample already in 5P7.4
to give a final NaCl concentration of 150 mM and the sample was allowed to
equilibrate overnight at 4 °C.

The concentrations of the purified spectrin

peptides was determined by absorbance values at 280 nm, using extinction
coefficients determined from their primary sequence by ProtParam (Parker &
Berkowitz, 1986).

4.9

Spectrin Peptide Characterization

The integrity of the peptide samples was analyzed by SDSpolyacrylamide gel electrophoresis (PAGE) as described below in section 2.12,
by amino-acid sequencing of the N-terminal residues (Biocore Facility,
University of Notre Dame, South Bend, IN) and by time of flight/matrix -
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assisted laser desorption ionization mass spectrometry (Wistar Mass
Spectrometry/ Sequencing Facility, Philadelphia, PA). To determine whether
the peptides formed aggregates in PBS7.4, the solution molecular masses of the
peptides, at 0 .1-1 mG/mL concentrations, were determined at 4 °C with an
absolute molecular mass determination instrument (PD2000; Precision
Detectors, Inc., Amherst, MA). The intensity of light scattered at 15° and 90°
from a 630-nm laser, and the refractive index were monitored as the peptide
under investigation eluted from a G-75 column. Data were analyzed to give
solution molecular mass distribution profiles (Freifelder, 1982).

4 .10

Elastase Digestion

An elastase solution (1 mG/mL elastase in 5 mM Tris-HCI buffer at pH
5.0) was prepared. Spectrin peptide solutions (lmG/mL) were dialyzed against
50mM Tris buffer at pH 8.75 (Ardelt, 1974). Enzyme/protein ratios (w/w) of
1:100 (Winograd et al, 1991), 1:50, 1:25 and 1:12.5 were used.

It was

determined that at room temperature the 1: 12.5 ratio showed complete
digestion in a 7-10 hour time frame. Digestion progression was monitored by
taking samples at numerous time points and by visualizing digestion products
with SDS-PAGE (section 2.12). The band intensities on the dried gels were
digitized with a Scanmann II scanner (Logitech, Freemont, CA) at a resolution
of 400 dpi. The relative protein content of individual bands was determined by
integration of digitized images in each lane, using the SigmaGel program
(Jandel Scientific Software, San Raphael, CA).

Time constants for the

disappearance of each peptide (-c8) were determined by fitting the initial band
intensity (Io) at t

=

0 and the remaining band intensity (I) at each time point (t),
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to a simple exponential decay curve, 1/10 = exp(thg). Molecular masses of the
initial peptides, as well as the digestion products, were estimated by comparison
with standards of known molecular mass.

4.11

Protein SDS-PAGE

The SDS-PAGE was conducted as described by Laemmli (Laemmli,
1970) with modifications .

The separating gel contained 16% (w/v)

acrylamide, 0.43% (w/v) N, N' - methylene bisacrylamide, 375 mM Tris (pH
8.8), 0.1 % (w/v) SDS, 0.03% (w/v) ammonium persulfate, 0.07% (v/v)
TEMED. The stacking gel was made of3.8% (w/v) acrylamide, 0.1% (w/v) N,
N' - methylene bisacrylamide, 125 mM Tris (pH 6.6), 0.05% (w/v) ammonium
persulfate, 0.07% (v/v) TEMED. Electrophoresis samples were prepared by
adding the appropriate amount of 6x SDS loading buffer to a protein sample.
The loading buffer contained 300 mM Tris-HCI at pH 6.8, 12% SDS, 0.6%
bromophenol blue, and 60% glycerol. The electrophoresis was run in a MiniPROTEAN II electrophoresis cell at a constant current of 30 mAmp. The gel
was stained in a solution containing 50% methanol, 10% acetic acid and .005%
coomassie brilliant blue, then destained in a solution containing 7% acetic acid.

4.12

Electroblotting for Amino Acid Sequencing

Prior to amino-acid sequencing the spectrin peptide was digested with
elastase and the product was separated with SDS-PAGE.

Immediately

following electrophoresis the samples were electroblotted onto a polyvinylidene
diflouride (PVDF) membrane, as directed by the manufacturer.

A ProBlott

membrane (Applied Biosystems) was wet with methanol for a few seconds and

26

then soaked in electroblotting buffer ( 1OmM CAPS at pH 11. 0 and 10%
methanol) for 5 minutes along with the electrophoresis slab gel.

The

transblotting sandwich was assembled and the electroblot was run, at 4 °C, in
the Mini Trans-Blot Cell (BioRad Laboratories, Hercules, CA) for about 90
minutes at 300mA and lOOV then removed and rinsed thoroughly with
deionized water. The membrane was then stained (0.1 % (w/v) coomassie blue;
40% (v/v) methanol; 1% (v/v) acetic acid) for 5 minutes followed by destaining
with several changes of 10% (v/v) methanol. The membrane was allowed to air
dry and then sent to the Amino Acid Sequencing Facility at the University of
Illinois Champaign for amino-acid sequencing of the first 9 amino acids in the
desired peptide fragment.

4.13

Spectrin Dimer Preparation

As described previously (LaBrake, 1993), human red blood cells
(RB Cs) were obtained from the local blood bank and used within one week of
withdrawal.

All steps were carried out at 4 °C unless specified otherwise.

RBCs were washed 3 times with 5 mM sodium phosphate buffer with 150 mM
NaCl at pH 8.0 (PBS8). White membrane ghosts were prepared by lysing the
washed RBCs with 20 volumes of 5 mM phosphate at pH 8.0 (5P8) and then
washing the membrane 3 times with the same buffer, according to the method
of Dodge et al. (1963). The spectrin dimer preparations were done according
to published methods (Ungewickell & Gratzer, 1978; Budzynski, et al., 1992).
The membrane ghosts were washed once with 0. 3 mM phosphate buffer at pH
7.6 (0.3P7.6), followed by incubation with 2-3 volumes of 0.3P7.6 for 30
minutes at 37 °C. After incubation at 37 °C , the membranous solution was
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centrifuged at 400,000 x g in an ultracentrifuge for 20 minutes.

The

supernatant containing the spectrin-actin complex was pooled and concentrated
with an ultrafiltration cell (Amicon, Danvers, MA) to a concentration of about
1.5 mG/mL. The spectrin concentrations for the experiments were determined
using an extinction coefficient at 280 nm of 1.0 (Clarke, 1971). The spectrinactin solution was loaded onto a gel filtration column (Sepharose 4B-CL,
Pharmacia, Piscataway, NJ) equilibrated with 25 mM Tris, 5 mM EDTA and
100 mM NaCl at pH 7.6 and eluted at a flow rate of 22 mL/hr for about 16
hours. The spectrin dimer fractions were pooled and stored at -80 °C.

4.14

Fourier Transform Infrared (FTIR) Spectroscopy

FTIR spectra were collected as described previously (LaBrake et al.,
1993). Samples at 10-30 mG/mL in 5P7.4 were used. Spectra were collected
using a Bio-Rad FTS-40 FTIR spectrophotometer with a triglycine sulphate
detector at the University of Illinois at Chicago. Typically, 1024 interferograms
were recorded, co-added, triangularly apodized and Fourier transformed to give
a single beam spectrum with a resolution of 4 cm· 1. All measurements were in
H 20 buffer, a semi-permanent cell equipped with CaF2 windows and a 6 µm
spacer from Graseby Specac Inc (Fairfield, CT) was used. A water vapor single
beam spectrum was collected in the presence of an empty cell and reduced N 2
purge. For each spectrin peptide a single beam spectrum was collected on the
spectrin peptide, on the buffer/background (filtrate from sample concentration)
and on a clean empty cell (air).
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4 .15

FTIR Data Analysis

All data manipulations were performed using either Spectra-Cale or
GRAMS software (Galactic Ind., Salem, NH) and were carried out as
previously described (LaBrake et al, 1993).

4.15.1

Absorbance Spectra

The IR absorbance spectra of the spectrin samples were calculated from
the single beam intensity spectra.

The log of the ratio of the single beam

spectrum of the sample of spectrin peptide to that of air was taken. In the same
way, the absorbance of the background referenced to air was determined.

4 .15 .2

Background Subtraction

To obtain the absorbance spectrum of a spectrin peptide corrected for
the contribution of the background, the background absorbance spectrum was
subtracted manually using GRAMS software. The subtraction was carried out
by varying the scaling factor of the background spectrum until the difference
spectrum displayed a flat baseline in the region of 1700-2000 cm· 1.

Peak

positions were obtained from the corrected absorbance spectrum.

4.15.3

Partial Least Square Analysis

The absorbance spectra of the spectrin peptides were analyzed using the
Dousseau & Pezolet (1990) method as previously described (LaBrake et al.,
1993). The spectra were prepared for analysis with Spectra-Cale software by
setting spectral limits from 1480 to 1720 cm· 1, adjusting a flat baseline with a
two-point baseline correction, setting the baseline to zero and normalizing the
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total intensity to unity. The analysis was carried out using the PLS-QUANT
option in the Spectra-Cale software. A training set of 14 spectra with known
secondary structure (Dousseau & Pezolet, 1990) were used to calculate the
calibration spectrum with a dimension of 25 and four secondary structural
element components: ordered a.-helix, disordered a.-helix, J3-sheet and other
(includes turns and random coil).

Thus, using the PLS-QUANT option of

Spectra-Cale, with the calibration spectrum, the relative content of the
secondary structural elements of our peptides was predicted from their FTIR
absorbance spectra.

4.15.4

Amide I Peak Position Identification

To obtain the amide I peak position the absorbance spectra were
smoothed using a FTT (Fast Fourier Transform) filter (cutoff of 6 cm-1) to
further remove sharp peaks associated with H20 vapor. Hopefully, smoothing
did not lower resolution as the halfwidths of the solution phase amide I peaks
are broad, ranging from -30-35 cm· 1, while the halfwidths of the vaporphase
H 20 peaks are comparatively narrow, -3 cm· 1. The peak position was then
chosen as the peak maximum.

4.16

Circular Dichroism (CD)

Thermally induced unfolding of the spectrin peptides and spectrin dimer
was monitored by CD at 222 nm, every 0.5 °C, using a Jasco 710 CD
spectrophotometer and a thermostated (water jacketed) cell with a 0.1 cm path
length at the University of Illinois at Chicago. The temperature was increased
continuously at a rate of 1°/min. All samples had an absorbance at 280 nm of -
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0.3 and were in the presence of either PBS7.4 or 5P7.4 buffer. A CD222 reading
was obtained every 0.5 °C. The molar ellipticity at 222 nm, 8222 (degree cm2
dmor

1
),

was calculated. To determine a-helical contents we used the method

described for dystrophin, which has a similar structure to spectrin, by using 8 222
=

-36,000 degrees cm2 dmor 1 to represent peptides with 100% a-helical

structure (Kahana et al, 1992).

4 .17

Fluorescence

Thermally induced unfolding of the spectrin peptides and spectrin dimer
was

monitored

by flourescence

spectroscopy,

using

Hitachi F-2000

fluorescence spectrophotometer equipped with a thermostated cell holder. A 1
cm path length cuvette was used, with sample stirring, while the temperature
was raised 1°/min and was monitored within the sample itself All samples had
an A2so

=

0.02 and were in the presence of either PBS7.4 or 5P7.4 buffer. An

excitation wavelength of 278 nm was used and the emission spectra were
collected between 315 - 385 nm every 2 °C, starting at 7 °C. The values of the
average emission wavelength, with

A.mean

defined as

A.mean =

l,h I l, IAX 1

(Royer et al., 1993; Royer, 1995), were calculated from values of intensity (h)
for each spectrum and used to monitor unfolding. This parameter is a more
suitable measure of unfolding than either simple intensity measurements at a
particular wavelength (Eftink, 1994), or a ratio of intensities at two
wavelengths (Steer & Merrill, 1995). Since A.mean incorporates the information
in the whole emission spectra, it is less noisy, and more sensitive to changes in
any region of the spectra than those obtained with other generally used
methods.
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4.18

Data Analysis of Thermally Induced Unfolding

We determined the temperature for 50 % unfolding {Tm) of the spectrin
peptides and the spectrin dimer and the entropy at this temperature, .1Sm, by
fitting the denaturation profile (fraction of unfolding versus temperature),
obtained either by fluorescence or CD methods, to a two state (native -...
unfolded) denaturation model. This was done by using a nonlinear least squares
minimization routine in conjunction with a series of equations that described the
system detailed below.

4.18.1

Baseline Correction

Well away from the transition, both states (native, N, and unfolded, U)
were observed to exhibit spectral properties (<I>) that were linear functions of
temperature. This baseline has commonly been approximated by a linear
relationship (Eftink, 1994; Shortle et al., 1988; Stafford, 1985):

*T
<l>u,o + bu * T

<l>N(T) = <l>N,O + bN

(1)

<l>u(T) =

(2)

where <l>N,o and <l>u,o are the spectral properties at a reference temperature (here
chosen to be 0 °C for convenience) of state N and state U, respectively, bN and
bu are the slope factors obtained experimentally and T was the temperature
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(°C).

The observed spectral properties, cj>(T), at any particular temperature

were then assumed to be a linear sum of the fractions of each component:

cj>(T)= (1-fu)* cj>N(T)+ (fu)*cJ>u(T)

(3)

where fu was the fraction of unfolded state at the temperature T.

4.18.2

Free Energy ofUnfolding
The fraction of unfolded state was derived from the equilibrium constant

expression :

K = fu/(1-fu)

(4)

where K was the unfolding reaction equilibrium constant in the two state
unfolding model.

Since K= exp(-AG/RT) where AG was the free energy

change for the unfolding reaction, fu was related to AG by the following
equation:

fu/(1-fu) = exp(-AG/RT)= exp(AH-TAS)/RT

(5)
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where MI and AS were the enthalpy and entropy change for the unfolding
reaction.
We have used two methods to analyze our data that differ according to
their AG dependence on temperature. In the first method we used a linear free
energy dependence of AG on T, i.e., the heat capacity change for the unfolding
reaction (Cp) was equal to zero (Eftink, 1994; Shortle et al., 1988; Hancock &
Hsu, 1997). With this method, at the temperature where 50% of the peptide
was unfolded T=Tm, K=l and AG=O, then AH=TmAS. As Cp was assumed to
be zero then MI and AS were temperature independent and thus AS=ASm and
MI=TmASm in equation (5):

fu/(1-fu) = exp(-ASm(T - Tm))/R(T+273)

(6)

This assumption was only an approximation, since Cp has been shown to
be non-zero for most proteins (Sturtevant, 1977; Schellman, 1987; Becktel &
Schellman, 1987; Shortle et al., 1988). However, this approximation is still
being used (Eftink, 1994; Hancock & Hsu, 1997) since the relative magnitude
of Cp is often not large compared to MI, AS and T. In more rigorous terms,
the curvature o2 AG/oT 2 = -Cp/T is small compared to the slope oAG/oT=ASm.
In the second method used to analyze the unfolding profile, a more rigorous
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equation that allows for non-zero Cp values (Shortle et al., 1988; Becktel &
Schellman, 1987) was used:

fu/(1-fu) = exp ((fm(AS - Cp) - (AS+ Cp)T - Cpln(T/Tm)Y(R(T+273))) (7)

CHAPTER V

RESULTS

5.1

Characterization of Properly Phased a-Spectrin Peptides

5.1.1

Molecular Masses

All spectrin peptides were purified to >90% purity as seen by SDSP AGE (for example, Appendix I - Fig. 2A and B, Fig. 3A; Appendix II - Fig.
2A, B and C; Fig. 1). Occasionally, trace amounts of GST at
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k:Da were

also detected (Appendix II - Fig. 2B and C), yet most preparations provided
samples with at least 95% purity.
The theoretical molecular masses calculated from the ammo acid
sequence, experimental molecular masses as estimated from the electrophoretic
mobility and from the time of flight/matrix-assisted laser desorption ionization
mass spectral analysis peptide masses for Spa52-156, Spa157-262, Spa263368, Spa52-262, Spa157-368, and Spa52-368 are summarized in Table I. It
was found that the values obtained from mass spectrometry were all within
0.1 % of the theoretical molecular masses. Solution molecular masses under
non-denaturing conditions were also obtained by 15° and 90° light scattering
intensity data in both 5P7.4 and PBS7.4.

Most peptides, at

~

lmG/mL,

exhibited molecular masses within 10% of theoretical (Table I), suggesting that
they were all monomeric in solution. It was shown that this light scattering
technique was able to detect oligomers of the peptide Spal-446 at this
35
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Figure 1

~

SDS-PAGE of the elastase digestion products of Spa.157368.

The first lane contained molecular mass standards.

Subsequent lanes (lanes 2-14) contained an aliquot of each
digestion reaction ended at various times, except for 0 h which
contained no elastase: 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5,
and 6 h. Intensities of the band for Spa.157-368 (27.2 kDa)
decreased as a function of elastase digestion time. Spa.157-368
eventually yielded fragments at 16.0 and 14.3 kDa.

Table 1 - Peptide Molecular Masses (kDa)
Protein

theoreticaI3

mass
sEectrometryb

electrophoresisc

light scatteringa
5P7.4e

PBS7.4r

Spa52-156

12.65

12.64

12.2

11.9

11.4

Spa.157-262

12.24

12.39

12.3

9.8

12.4

Spa263-368

12.06

12.21

12.1

12.7

12.3

Spa.52-262

24.87

24.86

28.8

21.5

23.5

Spal57-368

24.28

24.43

27.2

26.3

25.9

Spa52-368

36.92

36.92

37.2

35.1

34.4

Values calculated from the amino acid sequence.
Obtained from time of flight/matrix-assisted laser desorption ionization mass spectrometry. Values from one run, all fall within 0.1% of
theoretical values.
0
Estimated from 16 % SDS-PAGE data with IO% uncertainties.
d Average values obtained from PDI data, see section 2.9, generally from two runs, all fall with 10% uncertainties.
•Samples in buffer of 5 mM phosphate at pH 7.4.
cSamples in buffer of 5 mM phosphate and 150 mM NaCl at pH7.4.
a

b

w

-.l
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concentration. Considerable amounts of both dimer and trimer were detected
(Appendix II - Fig. 2).

5.1.2

N-terminal Amino Acid Sequencing

The first 8-9 amino acid residues obtained from N-terminal amino acid
sequencing agreed with the assumed sequences of the peptides.
5.1.3

Fourier Transform Infrared (FTIR) Spectra

The single-domain peptides (Spa52-156, Spa157-262 and Spa2633 68) all have the location of their amide I peak frequency centered at - 1652
cm- 1. The multiple-domain peptides, Spa52-262, Spa157-368 and Spa52-368,
are more similar to the spectrin dimer with peaks centered at -1651 cm -1. The
spectrin dimer had its peak centered at -1650 cm -l (Table II, Fig. 2). Results
on the relative content of secondary structural elements showed that Spa52156, Spa157-262 and Spa263-368 exhibited 35, 69 and 57 % helical content in
5P7.4, respectively. Spa52-262, Spa157-368 and Spa52-368 exhibited 69, 65
and 82 % helical content in 5P7.4, respectively.

In the same conditions the

spectrin dimer exhibited 67 % helical content (Table II).

5.1. 4

Circular Dichroism (CD) - Helical Content

At 20 °C no significant difference was found for a peptides helicity in
PBS7.4 versus 5P7.4 (Table III). The helical contents for Spa52-156, Spa157-

Table 2 - Structural Properties Derived from FTIRa
Secondary Structural Elementsb
Proteinc

Amide I (cm- 1)d

% Helix

% 13 - sheet

% Other

Spa.52-156 (n = 2)

1652.0 ± 0.7

35 ± 10

21 ±7

36±6

Spa.157-262 (n = 2)

1652.0 ± 0.4

69± 3

9±5

21 ±0

Spa.263-368 (n = 3)

1652.3 ± 0.2

57± 5

14±4

29±2

Spa.52-262 (n = 2)

1650.8 ± 0.3

69±0

12± 2

20±2

Spa.157-368 (n = 2)

1650.7 ± 0.2

65 ±4

13 ± 2

23 ± 3

Spa.52-368 (n = 2)

1650.6 ± 0.1

82± 1

6±1

13 ± 1

Spectrin dimer (n = 1)

1649.9

67

19

32

All runs were at room temperature, - 20 °C, and were in 5P7.4.
PLS analysis of FTIR spectra
c n always represents the number of runs.
d All errors were the standard deviation of multiple runs (crn. 1).
a

b

w

\0
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Figure 2

FTm spectra of Spa52-156 (dashed olive line), Spa157-262
(dashed blue line), Spa263-368 (dashed green line), Spa52262 (dotted magenta line), Spa157-368 (dotted purple line)
and Spa52-368 (solid yellow line) normalized to peak area.
The average amide I peak center for the single-domain peptides
was 1652 cm- 1 and was 1651 cm- 1 for the multiple-domain
peptides. The amide I peak height reflects the helicity.

The

greatest average helicity was found for the three-domain peptide
Spa52-368 (82 %). The two-domain peptides, Spa52-262 and
Spa157-368, followed with helicities of 69 % and 65 %,
respectively.

Finally the single-domain peptides, Spa52-156,

Spa157-262 and Spa263-368, showed the least helicity m
general with values of 3 5 %, 69 % and 57 %, respectively.
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Table 3 - Structural Properties Derived from

cn•,b,c

% helix

Protein
5P7.4

PBS7.4

Spa.52-156

48 ± 1(n=3)

52 ± 3 (n = 3)

Spa.157-262

72 ± 2 (n = 3)

75 ± 3 (n = 3)

Spa.263-368

58 ± 2 (n = 3)

61±1 (n=3)

Spa.52-262

77 ± 3 (n = 2)

75 ± 2 (n = 2)

Spa.157-368

70 ± 2 (n = 3)

72 ± 2 (n = 3)

Spa.52-368

81±2 (n = 5)

79 ± 2 (n = 4)

Spectrin dimer

53 ± 6 (n = 3)

60 ± 10 (n = 3)

• All runs were at room temperature, - 20 °C.
n always represents the number of runs. Generally two separate protein preparations of each peptide were used. No
variation outside of the error found for separate runs on one preparation was found for the error of the two preparations.
0
All errors were the standard deviation of multiple runs (crn-i)
b

~

N
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262 and Spa263-368 were 48, 72 and 58 % in 5P7.4 and 52, 75 and 61 % in
PBS7.4, respectively. The helical contents for Spa52-262, Spa157-368 and
Spa52-368 were 77, 70 and 81 % in 5P7.4 and 75, 72 and 79 % in PBS7.4,
respectively. The helical contents for the spectrin dimer were 53 % in 5P7.4
and 60 % in PBS7.4.

5 .2 Elastase Digestions
The results of elastase digested Spa52-262 and Spa52-368 were
published (Appendix II). Spa52-262 was digested to 16.5 kDa, 14.5 kDa and
12.9 kDa bands (fragments). The first six residues of the most prominent band,
14.5 kDa, were GSSYHL, as shown by N-terminal amino acid sequencing. The
residues GS were from the thrombin digestion site and the rest corresponded to
amino acid residues 52-55 of a-spectrin. Spa52-368 was first digested to 30.5
and 28.3 kDa bands and next to 16.0 and 14.2 kDa bands.

The first six

residues of the most prominent band, 14.2 kDa, were also GSSYHL.
Spa157-368 appeared as a single band at 27.2 kDa in the presence of a
mild contamination at -20 kDa (Fig. 1, lane 2). Spa157-368 was digested to
two bands of 16.0 and 14.3 kDa (Fig. 1, lanes 3-10). The first six residues of
the most prominent band, 14.3 kDa, were GSALKF, with GS corresponding to
the thrombin digestion site and ALKF corresponding to amino acid residues
15 7-160 of a-spectrin.
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5.3

Thermal Unfolding

As described in Chapter IV (Materials and Methods) two methods were
used to analyze our data. The data were fitted to equations 6 and 7 by the nonlinear curve fitting program provided by Origin (Microcal Software, Inc.,
Northampton, MA) to give the parameters: AS, Tm and Cp. Standard errors of
these parameters were also obtained from the program. Parameters obtained
with the assumption that Cp=O (Eqn. 6) of a representative CD spectrum of
Spa.52-156 were as follows, ASm = 526.9 ± 1.2 J/mol•deg and Tm= 44.0 ± 0.1
°C. The parameters obtained without assuming Cp = 0 (Eqn. 7) were AS =
526.9 ± 392.9 J/mol•deg, Tm= 44.0 ± 558. 7 °C and Cp = -0.02 ± 464.24.

The

curve fitting with equation 7 gave essentially the same AS and Tm values as the
curve fitting with equation 6. The value for Cp obtained from equation 7 was 0.02, which was much less than the value for AS (527 J/mol•deg).

This

justified the linear AG approximation (Eqn. 6) since the curvature B2AG/BT 2 = Cp/T (Becktel & Schellman, 1987) was thus small compared to the slope
BAG/BT

~

AS. Since AG in equation 7 was relatively insensitive to Cp over

small T ranges when Cp <<AS, the fitting of experimental data to this equation
resulted in large indeterminacies for all three thermodynamic parameters. In
particular, the calculated standard error of the parameter Cp was quite large (0. 02 ± 464.24). This indeterminacy also resulted in relatively large errors for Tm
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and AS, but yielded Tm and AS values substantially identical to those determined
by the use of equation 6. As well, the overall X2 of the fit did not improve, with
values of 0.028 and 0.029 for equations 6 and 7, respectively.

We thus

concentrated on the parameters obtained from equation 6 (with the assumption

Cp=O).
The values of Tm (°C) and ASm (J/mol•deg) are summarized in Table IV
and Table V, respectively.

It was found by both CD and fluorescence that

spectrin dimer exhibited no difference in Tm in both high salt (HS) and low salt
(LS) buffer, with a value of ~47 °C for the Tm (Table IV). This feature was also
found for all of the multiple-domain peptides (Spa52-262, Spa157-368 and
Spa52-368). In the single-domain peptides (Spa52-156, Spa157-262 and
Spa263-368) the Tm was 48, 58 and 59 °C in LS buffer and 51, 54 and 63 °C in
HS buffer, respectively, for fluorescence and 45, 55 and 52 °C in LS buffer and
44, 53 and 57 °C in HS buffer, respectively, for CD.
On average the HS to LS ratio of ASm increases with an increasing
number of domains, gradually approaching the value for the spectrin dimer (Fig.
3). This ratio represents the difference in the cooperativity of the transitions
between the HS and LS conditions.

To express the result that suggests

multiple-domains have an increased HS/LS ratio for ASm we compared the
actual ratios for the multiple-domain peptides with the average ratio

Table 4 - Midpoint Temperature (Tm, °Ct
Fluorescence

Protein

Circular Dichroism

,c

5P7.4

PBS7.4

5P7.4

PBS7.4

Spa52-156

48 ±4 (n = 4)

51 ±2 (n = 4)

45 ±3 (n = 2)

44 (n =l)

Spal57-262

58 ±0 (n = 2)

54 ±2 (n = 3)

55 ±2 (n = 2)

53 ±0 (n = 2)

Spa262-368

59±1 (n=3)

63 ±1(n=2)

52 ±2 (n = 3)

57 ±2 (n = 2)

Spa52-262

51 ±2 (n = 8)

52 ±1 (n = 6)

50 ±1(n=3)

50±1 (n=3)

Spal57-368

61 ±2 (n = 4)

59 ±2 (n = 3)

59 ±1 (n = 3)

57±1 (n=3)

Spa52-368

52 ±3 (n = 6)

53 ±2 (n = 6)

54 ±1(n=3)

54 ±0 (n = 3)

spectrin dimer

46 ±0 (n = 4)

47 ±0 (n = 4)

48 ±0 (n = 2)

47(n=1)

Temperature with 50 % unfolded; Tm obtained from curve fitting of equation 6.
n represents the number of experimental runs of a single protein preparation. We had found that different protein preparations gave little
variation in experimental observations.
c All errors were the standard deviation of multiple runs (crn _1).
a

b

.i::.

O'I

Table 5 - L\Sm (J/molcdeg)8
Fluorescenceb,c

Protein
PBS7.4 (HS)

5P7.4 (LS)

Spa.52-156

424 ± 83 (n = 4)

Spa.157-262

Circular Dichroism
PBS7.4 (HS)

5P7.4 (LS)

358 ± 100 (n = 4)

Ratio
HS/LS
1.19

524

(n = 1)

507 ± 91 (n = 2)

Ratio
HS/LS
1.03

806 ± 33 (n = 3)

890 ± 25 (n = 2)

0.91

798 ± 83 (n = 2)

981 ± 17 (n = 2)

0.81

Spa.263-368

1214±33 (n=2)

1264 ± 158 (n = 3)

0.96

607 ± 75 (n = 2)

657 ± 141(n = 3)

0.92

Spa.52-262

765 ± 42 (n = 6)

615 ± 33 (n = 8)

1.24

840 ± 33 (n = 3)

615 ±25 (n=3)

1.36

Spa.157-368

1097 ± 67 (n = 3)

1064 ± 25 (n = 4)

1.03

1048 ± 67 (n = 3)

1039 ± 67 (n = 3)

1.01

Spa.52-368

1081±75 (n = 6)

757 ± 100 (n = 6)

1.43

981 ± 67 (n = 3)

765 ± 42 (n = 3)

1.28

Spectrin
dimer

3658 ± 524 (n = 4)

1430 ± 125 (n = 4)

2.56

948

624 ± 17 (n = 2)

1.52

(n = 1)

aEntropy at 50 % unfolded ; ASm obtained from curve fitting of equation 6.
n represents the number of experimental runs of a single protein preparation. We had found that different protein preparations gave little
variation in experimental observations.
c All errors were the standard deviation of multiple runs (crn-1).
b

-.l
"""
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Figure 3

Average ASHslASLS ratios of the spectrin peptides and of the
spectrin dimer for fluorescence and CD. The average ratios

for the single, Spa.52-156, Spa.157-262 and Spa.263-368, and
two-domain peptides, Spa.52-262 and Spa.157-368, are shown
along with the ratios of the three-domain peptide, Spa.52-368,
and the spectrin dimer. On average the single-domain peptides
showed no salt effect (fluorescence) or the opposite effect (CD)
of the spectrin dimer. For both techniques the effect was seen to
increase, towards the end of the effect seen for the spectrin
dimer, as the number of domains increased.
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of their parts.

For example, the ratio of Spa52-162 was 1.24 for the

fluorescence data and the average ratios for Spa52-156 and Spa157-262 was
1.05. The ratio of these two values (RR) was 1.2. Similarly the RR value for
CD data was 1.5. The RR of ~S for fluorescence and CD, respectively, for
Spa157-368/Spa157-262, Spa263-368 was 1.1 and 1.2; and for Spa52368/Spa52-156, Spa157-262, Spa263-368 was 1.4 and 1.4. The ratios of
~Sm

in HS buffer to

~Sm

in LS buffer show the effects of the addition of 150

mM NaCl to the buffer (Table V). On average no salt effect was seen for the

single-domain peptides (Fig. 3). The ratio was seen to increase for both two
repeat (Spa52-262 and Spa157-368) peptides in comparison to their
individual parts (Spa52-156, Spa157-262 and Spa263-368). The same was
seen for the ratio of the three domain peptide (Spa52-368) in respect to its
individual parts (Spa52-156, Spa157-262 and Spa263-368 or Spa52-262
and Spa157-368). The salt effect ratio found for a123 begins to approach that
of spectrin dimer (Fig. 3).

CHAPTER VI

DISCUSSION

6.1

Peptide Stability from FTIR and CD Studies

The shifts in amide I peak positions from 1651 cm- 1 to 1652 cm- 1 seen
with the smaller peptides (Spa52-156, Spa157-262 and Spa263-368) are
consistent with weaker hydrogen bonding and a larger fraction of disordered
helix, as discussed previously in Part II (Menhart et al., 1996). In another FTIR
study of the spectrin dimer, it was found that the peak center frequencies upshifted 3 cm- 1 when

the spectrin dimer was treated with the denaturing

conditions of SDS and by 1 cm- 1 when treated with NaOH (LaBrake et al.,
1993).
At the high concentrations needed for FTIR, generally >I 0 mG/mL, the
peptides studied were found to precipitate in PBS7.4.

The single-domain

peptides in particular were found to be precipitated at high concentrations (>5
mG/mL) when in PBS7.4. This problem was not present at the concentrations
used for the collection of CD spectra (<0.5 mG/mL). As a result the helicity of
the peptides in PBS7.4 versus 5P7.4 was obtained only by CD methods. It was
found that at room temperature there was no difference in helicity for either
spectrin dimer or the spectrin peptides in the different ionic strength buffers.
This finding was supported by another study in which the helicity of the spectrin
51

52

dimer in PBS7.4 versus 5P7.4 was not seen to vary as monitored by FTIR
(LaBrake et al., 1993).
In general the helicity of the peptides is seen to increase with the total
number of structural domains it contains as monitored by both FTIR and CD
(Table II, Table III). The one anomaly in this trend was found in the seemingly
high percentage of helicity for the single-domain peptide, Spa.157-262. This
could possibly be explained by the suggested presence of a disulfide between
Cys(167) and Cys(224) (Mitchell, 1997). It has been shown that generally
disulfide bonds structurally stabilize a protein (Cantor & Schimmel, 1980).
Both the helical content (Table II) and the amide I center peak
frequency (Fig. 2) of the peptides showed that multiple-domain peptides were
better folded, with both greater helical contents and stronger average hydrogenbond strength than found for their individual parts.

6.2

Peptide Stability from Elastase Digestion Studies

A triple-helical bundle model has been suggested for the 106-amino
acid sequence motif In this model the three helices are aligned side by side,
with the first and third parallel and the intervening second helix antiparallel
(Speicher & Marchesi, 1984; Parry et al., 1992; Speicher et al., 1993). X-ray
diffraction studies of one such sequence motif unit from a non-erythroid
spectrin support this model (Yan et al., 1993).

In these x-ray studies, the

peptide used was found to form a homodimer containing two triple-helical
structures, in which two of the three helices are contributed by one monomer
and the remaining helix by the other monomer. It is thought that this peculiar
arrangement may be an artifact of crystallization, and the true structure of a
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single unit may be similar to the earlier suggested triple-helical bundle with a
zigzag arrangement of the helices (Yan et al., 1993). This arrangement aligns
the N- and C-terminal residues at opposite ends of this triple-helical bundle, and
thus sequential motifs are thought to be linked in tandem in intact spectrin,
producing a very long rod-shaped molecule, approximately 100 nm in length, as
seen by electron microscopy (Shotton et al., 1979). Recently, an NMR solution
structure of a sequence motif unit from chicken brain a-spectrin has been
solved (Pascual et al., 1997) and it too supports the suggested triple-helical
bundle model (Fig. 4).
We have used the backbone coordinates of the x-ray structure (Yan et

al., 1993) and fitted them to our peptides.

Side chains were added to the

backbone a carbons and simple energy minimization was applied to provide a
working model for our peptides (Fig. 5).
Elastase digestion data suggested that the multiple-domain peptides
(Spa52-368, Spa52-262 and Spal57-368) were digested to bands of 12-15
kDa, corresponding to 100-130 amino acid residues.

Thus the digestion

products were likely to be fragments folded into a structural domain which
consisted of about 106-amino-acid residues.
Throughout the incubation of Spa52-262 with elastase, digestion
products appeared at 16.5, 14.5 and 12.9 kDa. The prominent band was at
14.5 kDa. When the N-terminal sequence data, the fragment size (-123 amino
acid residues for 14.5 kDa molecular mass) and the elastase digestion sites at
the C-terminal region were considered it was found that the potential peptides
for this fragment corresponded to a fragment containing residues 52 to 171,
174 or 179. Assuming that the 16.5 kDa (-140 amino acid residues) band had
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AB loop

Helix A

~

Helix C

Figure 4

NMR solution structure of chicken brain a-spectrin
(Pascual et al., 1997). The structure is of a single
domain of chicken brain a-spectrin (16th domain).
The different helices are labeled as Helix A (yellow),
Helix B (red) and Helix C (blue). Helix A is the Nterminal helix. The loop and tum linking the helices
are grey.

55

Figure 5

Model of Spa.52-262. The model was created by fitting our
sequence to the backbone coordinates of the x-ray structure.
Energy minimization was applied to provide a working model
for our peptide. The triple helical bundles have been designated
as helices A, B and C, starting with the most N-terminus helix.
The loops are designated by the regions they link, i.e., the loop
connecting Helix A and Helix B is termed the AB loop. The
structure of the second domain is designated by the prime
symbol. All loops are colored grey, Helix A is yellow, Helix B is
red and Helix C is blue.
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the same N-terminus as the 14.5 kDa, as the latter evolved from the former, the
16.5 kDa peptide fragments were then from residue 52 to residue 187 or 195.
Similarly for the 12.9 kDa band, the probable peptide fragments were from
residue 52 to residue 157, 158 or 164. These suggestions are summarized in
Table VI. Comparable results were seen for the digestion of Spal57-368 and
Spa52-368.

Spa52-368 was slightly different in that it was first digested to

-30 kDa fragments, presumably containing two sequence motifs, and then to
14.2 kDa, presumably containing a single sequence motif
When the digestion sites were examined in respect to their locations in
the working structural model it was found that the initial digestion appears to
occur within the loop region connecting helix A to helix B of the last domain of
the peptide (Table VI). This corresponds to the -16 kDa fragment seen for
both Spa52-262 and Spal57-368. By following the fragment size in this way it
is seen that the two domain peptides Spa52-262 and Spal57-368, continue to
be digested through the middle of helix A, producing -14. 5 kDa fragments, and
finally to the beginning of helix A, producing -12.5 kDa fragments. The initial
digestion in the AB loop corresponds to the - 30 kDa bands for the three
domain peptide Spa52-368.

Eventually these two domain sized fragment

produced in the Spa52-368 digest succumbed to form peptides that correspond
to the -16 kDa fragment and -14.5 kDa fragment seen in the Spa52-262
digest. When all of the digests were considered the most prominent fragment
was the -14. 5 kDa fragment.

This suggested that the remaining structural

domain gained significant stability, i.e., resistance to elastase digestion, from the
presence of a remaining section of helix A. The presence of the 12. 9 kDa band
suggested that the individual domain did have inherent structural stability and

Table 6 - Characterization of Elastase Digestion Fragments
Peptide

Spa52-262
(two domains)

Spal57-368
(two domains)

Spa52-368
(three domains)

Electrophoresis
Molecular Mass•
{kDa}
16.5 (-140 AAst
14.5 (-123 AAs)

N-terminal
sequenceb
{residue#}

Possible elastase
digestion sitesc
{residues}

Location of digestion sites
within triple helical modeld

157, 158 or 164
170, 171, 174 or 179

AB loop, 2nd domain
middle helix A, 2nd domain

12.9 (-109 AAs)

187 or 195

early helix A, 2nd domain

16.0 (-136 AAs)
14.3 (-121 AAs)

289, 293 or 297
273, 277 or 280

AB loop, 2nd domain
early helix A, 2nd domain

30.5 (-258 AAs)
28.3 (-240 AAs)

305, 309 or 313
389, 293 or 296

early helix B, 3rd domain
AB loop, 3rd domain

16.0 (-136 AAs)

same as Spa52-262

AB loop, 2nd domain

same as Spa52-262

early helix A, 2nd domain

14.2 (-120 AAs)

SYHL (52-55)

ALKF (157-160)

SYHL (52-55)

Obtained from 16 % SDS-PAGE data with 10 % uncertainties.
Amino acid sequence ofN-terminal residues. Residue numbers corresponding to those in a-spectrin were given in ( ).
c The sites were identified according to the N-terminal residue, the number of AAs and elastase site specificity.
d See section 4.2 for a description of the working structural model of a two-domain peptide.
e The abbreviation AAs represents amino acid residues.
a

b

u.
00
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was thus partially independent. The elastase digestion results suggested greater
C-terminal than N-terminal vulnerability in these peptides, since in all cases only
the N-terminal complete domain was observed as the final digestion product.
That is, Spa52-262 yielded only stable Spa52-156, not Spa157-262;
Spa157-368 yielded only stable Spa157-262, not Spa263-368; and Spa52156 yielded only Spa52-156, not Spa157-262 or Spa263-368.

A recent

NMR solution structure of an individual spectrin domain shows that the Cterminus of the single-domain, the AB loop and the N-terminus of the B helix,
is the most disordered portion of the molecule (Pascual et al., 1997). This AB
loop is also the most exposed portion of the structure, with the helices not as
tightly packed at the C-terminus of the peptide as at the N-terminus (Fig. 4).
This feature of less helical packing at the C-terminus of an individual structural
domain was also suggested by the x-ray model (Yan et al., 1993). Both the xray and NMR structures predict that position 28 of helix A is involved in an
open salt bridge with helices C and B, separating it from them at the C-terminal
end of the domain. Charged residues in this position are unusual as position 28
is a "d" position in the heptad ("abcdefg") sequence of coiled coils, generally
conserved as hydrophobic.

The C-terminus of the NMR peptide may be

disordered because it lacks the next domain and thus potential stabilizing
interactions with that domain. Our working model showed a coiling of the
helices which allowed for possible interactions between the C-terminus of the
first domain with the N-terminus of the second domain (Fig. 5). Both the
disorder found in the C-terminus of the NMR structure and the separation of
helix A from helix B suggested by both the NMR and x-ray structures would
seem to imply a vulnerable AB loop on the most C-terminus domain of a
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particular peptide and also a vulnerable C-terminus, to elastase digestion, for
this domain in general. The NMR and x-ray structures support the fact that
digestion of our a-spectrin peptides apparently did not occur between two
domains. Instead digestion was initiated at the C-terminus end of each peptide
and then continued, eventually producing only the N-terminal domain of that
peptide. In each case this N-terminal domain was most prominently present as
the -14 kDa fragment, near but slightly larger than the expected size of 12.5
kDa.

This probably reflects the fact that the remaining, most N-terminal,

domain gains significant structural stability from the presence of the first 10-20
amino acid residues of the next domain's helix A and as a result region beyond
the first 10-20 residues in helix A was the preferred digestion site. The working
model described above suggested that this stability would come from
interactions between the AB loop region of the first domain and the helix A' of
the next (Fig. 5). The larger fragments were eventually all partially converted
to the smaller fragments. Thus even though further digestion was possible, as
seen by the appearance of the 12.5 kDa band in some of the digests, it was
apparently not favored.
These results suggested that the digestion began at the last domain of a
peptide and continued towards the peptides N-terminal region, favoring
intermittent fragments that contained a full domains plus a portion of helix A
(-10-20 residues) of the next domain. The smallest fragments obtained (12.5
kDa) corresponded to -106-amino-acid residues, thus the results also suggested
that digestion beyond this point caused a substantial loss of structure and rapid
digestion to smaller fragments that were not detectable by SDS-PAGE. These
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results support the hypothesis that while the single-domain helical bundles are
stable folded units but are not necessarily completely independent.

6.3 Thermally Induced Unfolding by Fluorescence and CD
Cooperativity is a measure of how much change occurs in one variable
in response to a change in another variable. In other words, how sensitive is
one variable with respect to another in protein unfolding.

Cooperativity

reduces intermediate states and favors either the native or the unfolded states.
For example, a protein with high cooperativity, would remain essentially folded
upon temperature increases until the temperature approaches the midpoint of
unfolding temperature (Tm). Once the midpoint temperature was reached, the
unfolding would occur rapidly.

The sharpness of the transition would thus

reflect the level of cooperativity of a transition. Thus the unfolding of various
peptides can be monitored, with more (broader transitions) or less (sharper
transitions) unfolding around the midpoint temperature representing a more or
less cooperative transition, respectively.
In our case we were measuring the sensitivity of protein unfolding, with
respect to temperature, as monitored by changes in flourescence or CD222.
Representative fluorescence and CD spectra of Spa.52-368 are shown (Fig. 6 &
Fig. 7). The less change in temperature that was required to cause a large
change in A.mean or CD222, the more cooperative the transition for the peptide. In
both figure 6 and figure 7 the broader unfolding in LS buffer could be seen in
the plots of fu.
ASm , obtained from equation 6 was a measure of the cooperativity of
the unfolding. A sharp transition with a steep AG dependence of temperature
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Figure 6

Fluorescence-monitored unfolding and fu of Spa.52-368.
Fluorescence studies of thermal unfolding of Spa.52-368.
Temperature-mediated unfolding was monitored by flourescence
for Spa.52-368 in LS buffer (I) and in HS buffer (If!). A, The
mean emission wavelength, A.mean, was used at each temperature.
B, The fraction unfolded, fu, from equation 6 was used at each
temperature.
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Figure 7

CD-monitored unfolding and fu of Spa.52-368. CD studies of
thermal unfolding of Spa.52-368.

Temperature-mediated

unfolding was monitored by CD for Spa.52-368 in LS buffer (D)
and in HS buffer(•). A, The molar CD,

8222,

was used at each

temperature. B, The fraction unfolded, fu, from equation 6 was
used at each temperature.
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implies a high value of ASm. This could be seen as a phenomenon familiar to
the Hill constant used to describe bound and unbound states. High values of
the Hill constant represent sharp transitions, while low values represent broad
transitions. In our system, lower values of ASm represented a broad unfolding
transition, whereas large values of ASm represented a sharp transition.

An

example of this can be seen in the fu plots of Spa.52-368. When the unfolding
curves were compared on the same scale the LS unfolding curves were more
broad and had lower values of ASm than their respective HS unfolding curves,
which were more sharp and had higher values of ASm.
We suggest that high cooperativity (sharp transition) is the result of a
large number of molecular interactions within the system studied. The unfolded
state is presumed to involve fewer molecular interactions. Entropy is commonly
thought of as a measure of disorder. Assuming the unfolded state of all peptides
to be similar and to be highly disordered, we may estimate the degree of
ordemess in a native state that is stabilized by molecular interactions. A native
state with a larger number of molecular interactions would remain in an ordered
state and exhibit more cooperative unfolding (high ASm) whereas a native state
with less molecular interactions would remain in a less ordered structure which
would exhibit less cooperative unfolding (low ASm).
We used baseline correction to compensate for sloping regions either
before (native state) or after (denatured state) of our CD and fluorescence
unfolding curves (section 4 .19. 2). These types of corrections have been widely
used (Lehrer & Stafford III, 1991; Eftink, 1994) and have been rationalized as
due to intrinsic temperature dependence of the spectroscopic properties of the
chormophores involved.

Such behavior of the intrinsic fluorescence of the
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indole

chromophore

of tryptophan

in

isolated

form,

1.e.

N-acetyl-

tryptophanamide has been observed and supports this treatment (Freifelder,
1982).
However, recently it has been shown that changes in the signal away
from the transition region may reflect actual "pretransition" (Holtzer et al 1983)
unfolding for local regions of the molecule (Holtzer & Holtzer, 1992; Lovett et

al., 1996; Holtzer et al., 1997). However, this type of pretransition behaviour
does not preclude a cooperative transition involving the bulk of the molecule.
We were primarily interested in the larger cooperative transition.

Thus we

treated the smaller unfolding transition as baseline, and obtained slope factors
for these regions. These slope factors thus may reflect spectral properties of the
chromophores, or local pretransition unfolding. In any event, we do not ascribe
any physical meaning to these parameters in this study, concentrating instead on
the parameters involved in determining the larger, cooperative transition (Tm,
~Sm).

The Tm data for the single-domain peptides suggested salt-dependent
unfolding, a property quite different from that of spectrin and the multipledomain peptides whose Tm values were essentially similar. The fluorescence Tm
values for Spa263-368 seem to be high compared to the Tm values obtained
from CD. An explanation for this may be found by examining the unfolding
curves of this peptide for both fluorescence (Fig. 8) and CD (Fig. 9). The
fluorescence unfolding curve for Spa263-368 was different from a typical
unfolding curve in that it apparently contained an intermediate state. As the
first transition was poorly defined these data were fit to the same two-state
equation (6) used for all the data. In the fluorescence unfolding curve (Fig. SA)
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Figure 8

Fluorescence-monitored unfolding and fu of Spa.263-368.
Fluorescence studies of thermal unfolding of Spa.263-368.
Temperature-mediated unfolding was monitored by flourescence
for Spa.263-368 in LS buffer (0) and in HS buffer(•). A, The
mean emission wavelength, Amean, was used at each temperature.
The fluorescence unfolding curve for Spa.263-368 was different
from a typical unfolding curve in that it apparently contained an
intermediate state.

As the first transition was poorly defined

these data were fit to the same two-state equation (6) used for
all the data. B, The fraction unfolded, fu, from equation 6 was
used at each temperature.

S pa263-368

A
350 I

c:
ca
cu

~E

00

cJ:J•e•••••
•
oo 0

o

0 0
000 ct:JOoooooo

349

~o~•••••••••••••••••••• e

• •

o

oOO 0 0

348

l

0

1.4 ~
1.2

10

20

30

40

50

60

8

0

1.0

0

o~•••

0.8
'+- ::::>

80

70

0

oo•

0.6

0

0.4
0

....................8.~~· •

0.2
0.0

•
•

0

e

5P7.4
PBS 7.4

-0.2
0

10

20

30

40

50

Tern perature

60

70

80
0\

'°

70

Figure 9

CD-monitored unfolding and fu of Spa263-368. CD studies
of thermal unfolding of Spa263-368.

Temperature-mediated

unfolding was monitored by CD for Spa263-368 in LS buffer
(D) and in HS buffer(•). A, The molar CD,
each temperature.

8222,

was used at

When these curves were examined, in

particular the LS curve, two transitions seemed to be evident but
the relative contribution of the first to the entire unfolding curve
was small. B, The fraction unfolded, fu, from equation 6 was
used at each temperature.
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it appears that approximately half of the unfolding, from -348 nm to -349 nm,
occurs in the poorly defined transition. Thus the actual temperature for 50 %
unfolded was not clear.

Examination of the CD data showed that the

intermediate state might also have occurred there (Fig. 9A), but in this instance
the relative contribution to the entire unfolding curve was small. Thus the Tm
values for Spa263-368 obtained from CD were considered to be more reliable.
For Li Sm values, obtained from both CD and fluorescence data, it was
found that the multiple-domain peptides and spectrin dimer exhibited sharper,
more cooperative transitions in HS buffer relative to LS buffer (Table V).
However, it was found that the single-domain peptides, in general, exhibited
broader, less cooperative transitions for HS buffer relative to LS buffer. The
HS/LS ratio of the LiSm values suggested that the salt effect on the multipledomain peptides was greater than the effect seen for the individual domains.
Thus all our data suggested that peptides consisting of two or three motifs in
tandem are more faithful in reflecting the properties of the spectrin dimer.
The broader unfolding of spectrin in LS buffer that we have seen by CD
and fluorescence has been observed in other earlier studies.

Using optical

rotary dispersion and calorimetry techniques Ralston & Dunbar (1979) detected
broader thermal denaturation transitions for spectrin in 5 mM phosphate with
no NaCl than for spectrin in 5 mM phosphate with 100 mM NaCl. It has
similarly been seen by proton NMR that a wider unfolding range is found for
the thermal denaturation of spectrin dimer in 1.5 mM phosphate buffer with no
NaCl spectrin in 1.5 mM phosphate buffer with 150 mM NaCl (Begg et al.,
1994). The increased unfolding range in low salt is suggested to be the result of
helical destabilization in the absence of charge screening (Begg et al., 1994).
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They conclude that both configurational entropy and enthalpy play a role in the
overall flexibility of spectrin (Begg et al., 1994). In another study it has been
suggested that entropy drives the elasticity of spectrin, not the configurational
entropy of flexible coils, but rather the entropy from the reversible dissociations
of weak but specific intra/inter molecular contacts (Vertessy & Steck, 1989).
Their findings also suggest that these weak interactions may arise from
interdomain associations that could be broken, separating rather than denaturing
the independently folded domains of spectrin (Vertessy & Steck, 1989). Our
results on .::1Sm reflect an entropy difference for the transitions.

A more

cooperative transition corresponds to a high .::1Sm and thus to more molecular
interactions.

The multiple-domain peptides and spectrin showed a larger

change in .::1Sm from HS to LS buffer, suggesting the multiple-domain peptides
and spectrin dimer had more change in their number of interactions from HS to
LS buffer than the single-domain peptides.

Thus the results suggested that

largely the interactions affected by the ionic strength were the domain-domain
interactions, as the effect was seen to increase with increasing domain numbers
(Fig. 3). Domain-domain interactions have also been implicated by our FTIR
(increasing helicity and hydrogen-bond strength) and by our elastase digestion
(no evidence of digestion at domain junctions) results for the multiple-domain
peptides. Based on our results, we suggest that the location of these ionic
strength mediated interactions may be between the C-terminal area of one
domain, i.e., the AB loop region, and the N-terminal area of the following
domain, i.e., the first 10-20 residues in helix A' (Fig. 5).

CHAPTER VII

CONCLUSIONS

In Part I of this dissertation we found that the first amino acid residue of
the first structural domain of a-spectrin was 52 (Ser) (Lusitani et al., 1994).
In Parts II & III, we used the properly phased peptides of various
lengths and studied them using FTIR, resistance to proteolytic digestion, CD
and fluorescence to show that while the single-domain peptides were helical and
protease resistant structures, the multiple-domain peptides were more helical,
more resistant to proteolytic digestion and more true in their reflection of the
ionic strength mediated changes of spectrin.
The data presented in this dissertation provided evidence supporting the
hypothesis that while the 106-amino-acid sequence motifs were able to form
stable helical domains when properly phased, multiple-domain peptides were
needed to fully reflect the properties of the spectrin dimer.

The data also

suggested that the additional properties displayed by the multiple-domain
peptides were the result of the additional interactions that occurred between the
structural domains when linked in tandem. The identification of the specific
nature

of these

inter-domain

interactions

observations.
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SUMMARY
The 106 amino acid sequence motifs of spectrin have been suggested to fold into
s1able structural domains, consisting mostly of coiled coils of triple helices. With the advent
of molecular biology and biophysical techniques, structural studies of these spectrin 106
amino-acid structural domains became approachable. However one of the difficulties in
such an approach is to determine the correct phasing of the structural domains, which may
or may not coincide with the phasing of the sequence motifs. Proper identification of the
domain phasing is vital to the construction of s1able spectrin domains for molecular studies.
A previously published phasing shift for Drosophila a-spectrin indicated a downstream
phase shift of 26 amino acids for the structural domain (Winograd, E., Hume, D., and
Branton, D., 19<Jl, Proc. Natl. Acad. Sci. USA 88, 10788-10791). Using this phase shift,
we prepared a recombinant spectrin peptide with the sequence from residue #49 to residue
#155 of human erythrocyte a-spectrin, and found this peptide to be uns1able relative to other
peptides that we prepared.

Using several other recombinant a-spectrin peptides and

following the protease digestion approach, we digested spectrin peptides with elas1ase and
chymotrypsin and analyzed the amino acid sequence of the digestive products. We provide
the first experimental evidence in identifying the first amino acid residue of the first spectrin
domain in human erythrocyte a-spectrin as residue #52 (S).
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Underlying 1he cytoplasmic surface of 1he human erythrocyte membrane is a dense,
two-dimensional network of spectrin and o1her proteins 1hat provides support to 1he lipid
bilayer, and maintains 1he erythrocyte flexibility (1). Spectrin, which is comprised of aand P-subunits, plays a critical role in maintaining 1he architecture and 1herefore 1he
integrity of 1he red cell membrane. Many hereditary hemolytic anemias involve spectrin
mutations (2-7). In addition, several o1her proteins, such as dystrophin, alpha-actinin,
fibrin, etc. share many properties similar to 1hose of erythrocyte spectrin and are grouped
as 1he spectrin super-family (1). Thus it is important to understand 1he structural properties
of spectrin. However, little experimental information is available to describe 1he detailed
three-dimensional structure of spectrin.

Amino acid (8) and cDNA (9,10) sequence

analyses of human erythrocyte spectrin (will be referred to as human spectrin hereafter;
o1her types of spectrin will be clearly stated) reveal 1hat most parts of both subunits consist
of homologous sequence motifs. Each motif consists of about 106 amino acids in length.
There are 22 sequence motifs in tandem in 1he a-subunit and 17 sequence motifs in the

P-

subunit. These sequence motifs have been suggested to fold into stable structural domains,
consisting mostly of coiled coils of triple helices (11,12). With the advent of molecular
biology and biophysical techniques, structural studies of these spectrin 106 amino-acid
structural domains (spectrin domains) became approachable. Recently, the X-ray structure
of a homodimer of a 106-amino acid fragment in segment 14 of Drosophilia a-spectrin has
been published (13). However one of the difficulties in such an approach is to determine
the correct phasing of the structural domains, which may or may not coincide with the
phasing of the sequence motifs.
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Winograd et al. (14) provided experimental evidence from Drosophila a-spectrin
fragments to suggest a downstream phase shift of 26 amino acids for the structural domain
such that the first amino acid in a folded unit is residue #26 in the 106-residue sequence
motif. Assuming human a-spectrin has the same phase-shift as Drosophila a-spectrin, the
first amino acid at 1he N-terminal end of the first structural domain (AAl) would be residue
#49 (L), since residue #24 (I) is the first amino acid of the first sequence motif in human
a-spectrin (9). Based on information obtained from protease protection analysis (12),
Speicher et al. suggest that structural domains begin and end around residue #30 of the
sequence motif of a-spectrin (15). These phase-shifts have been used to construct structural
models or recombinant peptides. The Winograd phase-shift (14) was used to construct
recombinant peptides either of a-spectrin for X-ray studies (13) or for folding studies (16),
or of P-spectrin for supra-motif studies (17). The phase-shift of dystrophin was compared
with Winograd's phase-shift in spectrin and was found to be different by an upstream-shift
of 9 amino acids (18). The Speicher phase-shift (12) was used to construct recombinant
peptides for spectrin tetramer binding site studies (15). Kennedy et al. stated that the
phasing of the structural domain in P-spectrin is shifted approximately 20 to 30 residues
toward the COOH terminus compared with the phasing of the sequence motifs (19).
Not only do different published results suggest different amino acids as AA 1 for the
structural domain but different numbering systems for the amino acids in the spectrin
sequence are also used. Before the publication of a-spectrin cDNA results, E was residue
#1 according to Speicher and Marchesi (20). The human spectrin cDNA results detected
six additional amino acids located upstream of E to give MEQFPKE as the first seven amino
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acids in a-spectrin (9). Thus residue #1 (E) in the previous numbering system (20) is now
residue #7 in the cDNA numbering system (9) Both numbering systems are used in the
literature, though not necessarily clearly referenced, for all types of spectrin. Parry and
coworkers (21) identify the starting position of the first structural motif as residue 46, using
the numbering system of Speicher and Marchesi (20). Yan and coworkers (13) in their
work on segment 14 of Drosophila a-spectrin use the cDNA numbering system. We follow
the cDNA numbering system in this report (Fig. 1).
Using several recombinant human a-spectrin peptides and following the protease
digestion approach used by Winograd and coworkers (14),

we provide the first

experimental evidence in identifying the first amino acid residue of the first spectrin domain
in a-spectrin. Proper identification of domain phasing is vital to the construction of stable

spectrin domains for molecular studies. Our results show that the first spectrin structural
domain starts with residue #52 (S) (Fig. 1).
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MATERIAL AND METHODS
Spectrin Recombinant Peptides
The cDNA clone a.3 that contains the N-terminal region of the a-subunit (9) a
generous gift of Dr. B.G. Forget, Yale University School of Medicine, New Haven, CT,
was linearized with Sacll.and used as a template. Oligonucleotide primer containing
sequence corresponding to residues #1 through #9 of a.-spectrin, in a sense orientation, and
primer containing sequence corresponding to residues #159 through #167, in an anti-sense
orientation, were synthesized by National Biosciences (Plymouth, MN) and used to make
the spectrin construct of a peptide with the sequence of a.-spectrin from residue #1 to
residue #167 (Spa.1-167). 1 The published a.-spectrin sequence (9) was used. Similarly,
spectrin constructs of Spa.49-155 and Spa.49-167 were also prepared.

Some of the

oligonucleotide primers were synthesized by the Wells Center Oligonucleotide Synthesizer
Laboratory. The spectrin constructs were ligated into the BamHI and EcoRI sites of the
glutathione S-transferase (GST) expression vector pGEX-2T (Pharmacia, Piscataway, NJ).
These ligations were in-frame with the GST protein. The pGEX-2T vector contains a
thrombin cleavage site between GST and the inserted gene, i.e., spectrin construct. The
spectrin peptides were located immediately following the thrombin cleavage site. The
expression of fusion protein was under the control of a tac promoter. Thus, high, inducible
levels of fusion proteins were produced.
The overproduced fusion protein (GST-thrombin cleavage site-spectrin peptides)
was recovered from bacterial lysate and passed over a glutathione affinity column (e.g.,
glutathione-Sepharose 4B from Pharmacia), using published methods (22). The column,
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with the bound fusion protein, was extensively washed, followed by elution with buffer
containing fresh glutathione. The spectrin peptide was cleaved from the GST by
immobilired thrombin gel (CalBiochem, San Diego, CA) and eluted with GST and residual
uncleaved fusion protein from the gel. The mixture was passed over the glutathione affinity
column again to remove GST and residual fusion protein to give relatively pure spectrin
peptides.

If necessary, the peptides were further purified by fast protein liquid

chromatography (FPLC) with a Mono Q column (Pharmacia), using 40 mM Tris at pH 7 .5
and an NaCl gradient.
Enzyme

Dj~stion

and Peptide

Sequencin~

Elastase from porcine pancreas (Sigma) in 5 mM Tris at pH 5.0 was mixed with
a spectrin peptide at a weight ratio of 1:12.5, in 50 mM Tris at pH 8.8 and room
temperature.

Samples were taken from the mixture at various time points for gel

electrophoresis analysis. Similarly, chymotrypsin from bovine pancreas (Sigma) in 1 mM
HCl was mixed with spectrin peptide at a weight ratio of 1:400 (14), in 40 mM Tris with
125 mM NaCl at pH 7.5 and room temperature. 16 % polyacrylamide gel electrophoresis
was performed using electrophoresis buffer containing 0.5 % SOS. Low range protein
molecular weight standards (Gibco BRL, Gaithersburg, MD) at 43.0, 29.0, 18.4, 14.3, 6.2

and 3.0 kDa were used to guide the molecular mass calculation. For amino acid sequence
analysis, polyvinylidene diflouride membranes (Applied Biosystems, Foster City, CA) were

used for electroblotting. The amino acid sequencing of the digestive product was done by
the University of Illinois Biotechnology Center.

83
RESULTS AND DISCUSSION
Using Winograd's downstream phase-shift of 26 amino acids, we designed Spa49155, a peptide with 107 amino acid residues and with AAl at #49, to be a peptide that
included the first stable structural domain of human a-spectrin. However, Spa49-155 was
found to be unstable when compared to the other Spa-peptides that will be discussed below.
The electrophoretic gel of Spa49-155 purified by FPLC techniques exhibited several bands,
with the predominating band at 12.7 kDa and two minor bands at about 9.8 and 8.7 kDa
(Lane 1, Fig 2A). The molecular mass for Spa49-155 calculated from the sequence was
12. 7 kDa. Thus, we believe that the major band was that of Spa49-155 and the minor
bands were from degradation products of Spa49-155. In the presence of elastase, at a
weight ratio of 1: 12.5, Spa49-155 was quickly digested into smaller fragments. At t = 10
min, bands below 12. 7 kDa appeared at low intensities with the concurrent decrease in the
in~nsity of the 12.7 kDa band (Lane 2). As the digestion reaction with elastase proceeded

further, a steady decrease in the intensity of the 12.7 kDa band and an increase in the
intensities of the smaller bands were observed (Lanes 3, 5, 6 and 7). At t = 60 min, the
band at 12. 7 kDa was no longer detectable but faint bands below 12. 7 kDa were visible
(Lane 8). In contrast, under similar conditions, the peptide Spa49-167 was quite stable.
Spa49-167, with a molecular mass of 14.2 kDa calculated from the sequence, appeared as
a single band at 13.2 kDa on the gel (Lane 1, Fig. 2B). After 60 min digestion with elastase
under the cotxlitions listed above for Spa49-155, the Spa49-167 digestion product appeared
as a single band at 13.2 kDa (Lane 2). This band persisted at t = 2 hr (Lane 3). The
intensity of this band decreased at t = 3 hr (Lane 5), appeared as only a faint band at t =
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4 hr (Lane 6) and finally became not detectable at t

= 5 hr (Lane 7). Thus these digestion

results suggest Spa49-167 is folded into a more stable configuration than Spa49-155 and the
folded structure resists elastase digestion. The amino acid residues beyond #155 in Spa49167 provide elements to fold the peptide into a more stable structure.
The FPLC purified peptide Spal-167, with a molecular mass of 19.9 k.Da
calculated from the sequence, appeared as a single band at about 21.0 k.Da (Lane 2, Fig.
3A). Elastase digestion of Spal-167 (at weight ratio of 1: 12.5) resulted in two bands at
16.0 and 12.8 k.Da at t = 90 min. These two bands persisted in the digestion mixture at t

= 4 hr (Lane 3, Fig 3A).

The band intensity became undetectable at t

= 5 hr (not shown).

These data suggested that the digestion products were very stable peptides when compared
with Spa49-155, and had similar stability to the digestion product of Spa49-167, which also
withstood elastase digestion beyond 4 hr.
The N-terminal sequence analysis of the 12.8 k.Da fragment was found to be
EDSYHLQVFK, which aligned perfectly with #50- #59 in the a-spectrin sequence (Fig 1).
The elastase cleavage sites around this region of a-spectrin consist of #46 (G), #49 (L), and
#52 (S), and cleavage sites at the C-terminal end of the peptide consist of #151 (G), #154
(L), #155 (L), #157 (A), #158 (L) and #164 (V). We suggest that elastase cleaved at #49
(L) and at #157 (A) to give the peptide Spa50-157, which has a calculated molecular mass
of 12.8 k.Da. The first amino acid at the N-terminus of this digestion product was clearly

#50 (E), as indicated by the sequence analysis data. However, the last amino acid at the Cterminal end was less certain and was suggested by matching gel electrophoresis molecular
masses with calculated molecular masses. It was also possible that the digestion product
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was Spa50-154, Spa50-155 or Spa50-158, with calculated molecular masses of 12.5, 12.6
or 12.9 kDa, respectively. Thus the N-terminal sequence analysis of the elastase digestion
product (12.8 kDa) of Spal-167 suggests that the AAl is either #50, 51or52. If AAl is
#50 or #51, then the first stable structural domain of human a-spectrin is Spa50-154 or
Spa51-155, since the first motif of a - spectrin is comprised of 105 amino acid residues
(20), with a molecular mass of 12.5 or 12.6 kDa, respectively. Howev.er, we found that
the elastase digestion product of Spa49-155, a peptide that encompasses both #50-154 and
#51-155, did not produce any peptides with stability similar to those found in the digestion
products of the other peptides that we studied. This piece of evidence suggested that the Cterminal residue of the first structural domain was beyond #155. We conclude that the Cterminal residue is #156 and AAl is #52, giving a stable structural domain of Spa52-156.

Based on this conclusion, we suggest that Spal-167 contains a fully folded structural domain
which is able to resist elastase digestion. Elastase will only digest Spal-167 at sites prior
to #52 and after #156 to give the digestion product Spa50-157, with a molecular mass of

12.8 kDa. As discussed above, the digestion product of Spal-167 appeared as a band at
12.8 kDa (Lane 3, Fig 3A).
The N-terminal sequence analysis of the 16.0 kDa fragment was found to be
ETAEEIQERR, which aligned perfectly with #19 - #28 in the a-spectrin sequence. The
elastase cleavage sites around this region of a-spectrin consist of #17 (V), #18 (L) and #21
(A). The possible peptides were Spal9-154, Spal9-155, Spal9-157 or Spal9-158, with
calculated molecular masses of 16.3, 16.4, 16.6 or 16.7 kDa, respectively. We suggest that

the peptide is either Spal9-157 or Spal9-158. This peptide probably contains Spal9-51,
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the so called "helix 3" (12), which is also called "helix A" (11), plus the first stable
structural domain Spa52-156 and residue #157.
We also performed chymotrypsin digestion to obtain independent digestion products
from Spal-167. Chymotrypsin has cleavage sites different from those of elastase. After
90 min chymotrypsin digestion (at a weight ratio of 1:400), the single band of Spal-167 at
21.0 kDa (Lane 2, Fig. 3B) resulted in 6 bands at or below 21.0 kDa, with the smallest one
at about 14.5 kDa (Lane 3). The top band at 21.0 kDa was assumed to be the undigested
Spal-167, while the other 5 were chymotrypsin digestion products of Spal-167. The Nterminal sequence analysis of the smallest band at 14.5 kDa revealed an amino acid
sequence of KERVAE, which aligned perfectly with #39 (K) - #44 (E) of a-spectrin. The
chymotrypsin cleavage sites around this region consisted of #35 (Y), #38 (F) and #53 (Y),

and the cleavage sites at the C-terminal end of this peptide consisted of #140 (W), #160 (F)
and #163 (Y). We suggested that the chymotrypsin digestion product at 14.5 kDa was
Spa39-160, which has a calculated molecular mass of 14.5 kDa. It is also possible that the
digestion product was Spa39-163, with a calculated molecular mass of 14.9 kDa. The
chymotrypsin digestion data indicate that AAl is between residues #39 and #53, which

supports the conclusion obtained from the elastase digestion data to indicate that AAl is #52.
Thus our experimental results indicate that the first amino acid in human a-spectrin
structural domain is #52 (S), which corresponds to a downstream phase-shift of 29 amino
acid residues from the sequence motif reported by Speicher and Marchesi (20).

It is interesting to note that when we carefully studied the sequences published in
literature on works that reportedly use the Winograd phase-shift (13, 16, 17) to prepare
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recombinant peptides, we found that MacDonald et al. (16) had used a phase-shift
corresponding #49 (L) as AAl, whereas Byers et al. (17) and Yan et al. (13) had used a
phase-shift corresponding #52 (S).

We had mentioned earlier that in a modeling study,

Parry et al. (21) identify the starting position of the first structural motif as residue 46, with
their numbering system according to Speicher and Marchesi (20). Since this numbering
system starts with amino acid #7 (E) as #1, this modeling study has also placed AAl as #52.
Thus, AAl being #52 might have been suggested earlier without experimental evidence in
the literature. However, since the phase-shifts were not clearly stated as #52(S) in some
of these works (13,17), different phase-shifts have been used to prepare recombinant
spectrin peptides (16, 18, 19).

Our experimental studies show that amino acids #52 - #156 in human a.-spectrin are
folded as a stable structural domain. Preparation of this and related peptides for biophysical
studies will provide us with detailed structural information of spectrin.
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FOOTNOTE
1

Spal-167 - a peptide wi1h 1he sequence of a-spectrin from residue #1 to residue #167; GST

- gluta1hione S-transferase; FPLC - fast protein liquid chromatography; AAl - 1he first
amino acid at 1he N-terminal end of 1he first structural domain.
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FIGURE LEGENDS
Fig. 1. Amino Acid Sequence of Human Erythrocyte a-Spectrin from Residue #1 to
#167.

The cDNA numbering system is shown and used throughout this

presentation. Elastase ( l) and chymotrypsin (*) recognition sites are included.
Underlined arrows/asterisks indicate sites of elastase cleavage as reported here.
The amino acid residues in the first a-spectrin structural domain are shaded.
Fig. 2. SDS-PAGE (16 % gel) of elastase digestion products of a-spectrin peptides,
stained with Coomassie Brilliant Blue.
A: Lane 1, FPLC purified Spa49-155 (no elastase present); Lane 2, 10 min after
the introduction of elastase, at a peptide to enzyme weight ratio of 12.5: 1; Lane
3, 20 min; Lane 5, 30 min; Lane 6, 40 min; Lane 7, 50 min; and Lane 8, 60 min.
Lane 4, molecular weight standards.

B: Lane 1, FPLC purified Spa49-167 (no elastase present); Lane 2, 1 hr; Lane 3,
2 hr; Lane 5, 3 hr; Lane 6, 4 hr; and Lane 7, 5 hr. Lane 4, molecular weight
standards.
Fig. 3. SDS-PAGE (16% gel) of proteolytic digestion of Spal-167, stained with
Coomassie Brilliant Blue.
A: Elastase digestion of Spal-167. Lane 1, molecular weight Standards; Lane 2,
Spal-167 (no elastase present); Lane 3, 4 hr after the introduction of elastase, at
a peptide to enzyme weight ratio of 12.5 to 1. Bands at 16.0 and 12.8 kDa were
used for amino acid sequence analysis.
B: Chymotrypsin Digestion of Spal-167. Lane 1, molecular weight standards;
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Lane 2, Spal-167 (no chymotrypsin); Lane 3, 90 min after the introduction of
chymotrypsin at a peptide to enzyme weight ratio of 400: 1. Band at 14 .5 was used
for N-terminal amino acid sequence analysis.
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SUMMARY
The primary sequence of human erythrocyte spectrin contains repetitive

homologous sequence motifs of approximately 106 amino acids with 22 such motifs
in the a-subunit and 17 in the P-subunit. These homologous sequence motifs have
been proposed to form domains with a triple helical bundle type structure (Speicher,
D.W. and Marchesi, V.T. (1984) Nature 311, 177-180; Parry, D.A.D., Dixon, T.W.
and Cohen, C. (1992) Biophys. J. 61, 858-867). In this study, we show that these
sequence motifs, while they do form compact proteolytically resistant units, are not
completely independent. Peptides composed of two or three such motifs in tandem
are substantially more stable than peptides composed of a single motif, as measured
by proteolysis or by fluorescence or circular dichroism studies of urea or thermal
denaturation. Circular dichroism and infra-red spectroscopy measurements also
indicate that these larger, more stable peptides exhibit greater secondary structure.
In these respects, the peptides with tandem sequence motifs are more similar to
intact spectrin than the peptide with a single sequence motif Thus, we conclude
that peptides with more than one sequence motif model spectrin more adequately
than the peptides with one sequence motif, and that these sequence motifs are not
completely independent domains.
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INTRODUCTION
Human erythrocytes contain a dense, two-dimensional network of spectrin

and other proteins that provides support to the lipid bilayer and maintains
erythrocyte deformability (1). Spectrin, comprised of a- and P-subunits, plays a
critical role in maintaining the architecture and therefore the integrity of the red cell
membrane. Many hereditary hemolytic anemias involve spectrin mutations (2-4).
Thus, it is important to understand the structural properties of spectrin. The bulk
(about 90 % ) of the primary structure of spectrin is comprised of repetitive
homologous units of approximately 106 amino acids in length.

Several other

proteins, including brain spectrin (fodrin), dystrophin, and a-actinin, also have
similar repetitive amino-acid units in their sequences and are known as the spectrin
super-family (5).
A triple helical bundle model has been suggested for the 106-amino-acid
sequence motif in which the three helices are aligned side by side, with the first and
third parallel and the intervening second helix antiparallel (6-8). X-ray diffraction
studies of one such sequence motif unit from a non-erythroid spectrin support this
model (9). In these X-ray studies, the peptide used was found to form a homodimer
containing two triple helical structures, in which two of the three helices are
contributed by one monomer and the remaining helix by the other monomer. It is
thought that this peculiar arrangement may be an artifact of crystallization, and the
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true structure of a single unit may be similar to the earlier suggested triple helical
bundle with a zigzag arrangement of the helices (9, 10). This arrangement aligns the
amino- and carboxyl- terminal residues at opposite ends of this triple helical bundle,
and thus sequential motifs are thought to be linked in tandem in intact spectrin,
producing a very long rod shaped molecule, approximately 100 nm in length, as seen
by electron microscopy (11).
Circular dichroism (CD) (12, 13) and Fourier transform infra-red (FTIR)
( 14) studies of intact spectrin corroborate this model, indicating that spectrin
consists of a large proportion of a-helix. However, little experimental information
is available on the molecular structure of intact spectrin, in part due to its large size
and its structural flexibility which makes nuclear magnetic resonance or X-ray
studies difficult. Recombinant DNA methods have been used to prepare more
t.ractable fragments of spectrin which may serve as models for spectrin, as in the
aforementioned X-ray studies. However, the question of which fragment of spectrin
to choose as an appropriate model is important. The two factors that need to be
considered are phase and length of the fragment.
The issue of appropriate phase results from the fact that the homologous
sequences are joined in tandem with no obvious intervening delimiting sequences,
making the initial residue of the folded domains unclear. The start of the sequence
for an appropriate structural unit may not be assumed to coincide with the start of
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the homologous sequence motif in the primary sequence, especially since the onset
of the repetitive homologous sequence occurs with different phases in the amino
acid sequence of different members of the spectrin family of proteins.
We have used limited proteolysis to identify Sers 2 as the first residue of the
first structural domain of human erythrocyte a-spectrin (15). This places the start
of the first structural domain after the onset of the homologous sequence motif (6),
indicating that there is a fractional motif at the amino terminus in this protein.
Proteolysis experiments to delimit compact structural domains have also been done
by others on invertebrate spectrin (16), as well as on actinin (17) and dystrophin
(18). These studies have shown that the domain boundaries in these spectrin or
spectrin-like proteins are similar, and may be identified by a pair of highly conserved
tryptophan residues at positions 17 and 90 into the domain.
The issue of length is another matter. The proteolysis work has clearly
shown that a single sequence motif folds into a compact structure, but does this
structure capture the properties of the corresponding region in intact spectrin, or are
larger fragments necessary?

In order to assess this question, more detailed

examination of the proteins involved are necessary. We have addressed this issue
by producing peptides spanning the first three homologous sequence motifs of
human erythrocyte spectrin, both in isolation and in tandem, and comparing them to
intact spectrin in terms of their stability and spectral properties. We found that

104
peptides containing more than one sequence motif were notably more stable to
chemical and thermal denaturation, both thermodynamically and kinetically, and that
the properties were more similar to those of spectrin. Our results suggest that a
single 106-amino-acid unit of a-spectrin folds into helical bundles as a stable
structural unit but does not fully capture the structural and unfolding properties of
intact spectrin. However, peptides encompassing multiple 106-amino-acid sequence
motifs are much more faithful in capturing the properties of intact spectrin.

105
( e)

EXPERIMENTAL PROCEDURES
Purification of intact spectrin from human red blood cells was carried out as

before (19, 20).
For a-spectrin fragments, genes were constructed producing six different
fragments: Spa52-156t, Spa157-262, Spa263-368, Spa52-262, Spa157-368 and
Spa52-368. The peptide Spa52-156 encoded the sequence of human erythroid
a-spectrin (21) from residue Ser52 to residue Arg156, while the other peptides
spanned regions in spectrin indicated by the numerals in their names. These peptides
were expressed as fusion proteins with glutathione S-transferase in E. coli and
released by thrombin cleavage, as previously described (15).
Briefly, cDNA encoding the N-terminal region of the a-subunit of human
erythrocyte spectrin (clone a3, a generous gift of Dr. B.G. Forget, Yale University
School ofMedicine, New Haven, CT) was used as a template for PCR amplification
of the spectrin gene fragments. Restriction endonuclease sites were incorporated
into the primers to facilitate subcloning manipulations and incorporation into the
expression vector, pGEX-2T (Pharmacia, Piscataway, NJ).

For example, the

sequence of the 5' primer used in the synthesis of Spa52-156 was [5'cttaaatccTCCTATCACTTAca -3'], with upper case letters for the homologous
region encoding for the N-terminal amino acids SYHL. Lower case letters denoted
non-homologous nucleotides, while those underlined denoted the EcoRI site. The
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sequence of the 3' primer was [5'- cggiaattccta CCGCAGCAACTG -3'], with
upper case letters for the homologous region encoding for the C-terminal amino
acids QLLR. Those underlined denoted the Bamm site. All other peptides were
prepared with similar primer designs. Amplified fragments were initially subcloned
into a PCR cloning vector (pCRScript; Stratagene; La Jolla, CA) and were then
excised with appropriate restriction enzymes (Bamlfl and EcoRI) and cloned into
pGEX-2T.
These peptides were designed to start with proper phasing for folding
domains (15). Thus, Spa52-156, Spal57-262 and Spa263-368 consisted of the
first, second and third, respectively, single structural domains of a-spectrin. Other
peptides contained two (Spa52-262 and Spal57-368) or three {Spa52-368) such
structural domains. The two highly conserved tryptophan residues were at positions
17 and 90 in all six peptides.
Fusion proteins isolated from E. coli were treated with either thrombin resin
(15) or soluble thrombin (Enzyme Research Laboratories, South Bend, IN) to
release the spectrin peptides. The use of soluble thrombin involved incubation with
thrombin {lU/mg fusion protein) at 37 °C for about 3 h, until digestion was
complete as judged by SDS-P AGE. Thrombin was then inactivated by addition of
phenylmethyl-sulfonylfluoride (Aldrich; Milwaukee, WI) to 1 mM.

107
The rest of the purification procedure was as previously described, except
that the buffer pH for the monoQ FPLC (Pharmacia) purification step was changed
to pH 8.1, which moved the elution position for the spectrin peptides to
approximately 125 mM NaCl. The spectrin peptides were then further purified, if
necessary, by molecular sieve chromatography over a G-75 (Pharmacia) column in
5 mM phosphate buffer containing 150 mMNaCl at pH 7.4 (PBS).
Peptide purity was confirmed by SDS-PAGE (12 - 16 %). Peptides were
also checked by amino-terminal sequencing (Biocore Facility, University of Notre
Dame, South Bend, IN), and mass spectrometry using time of flight-matrix assisted
laser

desorption

ionization

(TOF-MALDI)

methods

(Wistar

Mass

Spectrometry/Sequencing Facility; Philadelphia, PA).
To determine whether the peptides formed aggregates in PBS solution, the
molecular masses of the peptides in solution, at 0.1 - 1 mg/ml concentrations, were
determined at 35 °C with an absolute molecular mass determination instrument
(PD2000, Precision Detectors, Inc.; Amherst, MA). The intensity oflight scattered
at 15 and 90 degrees from a 630 nm laser and the refractive index were monitored
as the peptide under investigation eluted from a G-7 5 column. Data were analyzed
to give solution molecular mass distribution profiles (22). The intensity of the
scattered light is proportional to the molecular mass of the molecules in solution,
with the following relationship: IJlo = 21t 2(n(5n/5c))2/NAA. 4r2

* (l+cos28) * M * c
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, where Io and 16 are the intensities of light with wavelength A scattered at angles 0
and

e degrees; n is the refractive index of the pure solvent; on/oc is the change in

refractive index of solutions of the molecule of interest with respect to its
concentration, c; NA is Avogadro's number; r is the distance between scattering
center and the detector; and M is the molecular mass {22). With the concentration
c determined from the refractive index signal (c=~n*oc/on), the molecular mass was
calculated from IJio. The above relation assumes ideal solution behavior. For real
solutions, this exact proportionality breaks down, and accurate determinations
necessitate extrapolation to c = 0. The use of light scattering in conjunction with
chromatography facilitates this extrapolation, as light scattering and refractive index
signals are monitored during the elution of the molecules from the column, during
which the concentration varied.
The precise protein concentrations were determined with absorbance values
at 280 nm (Azso), using extinction coefficients determined from the primary sequence
by the ProtParam tool on a molecular biology server (http://expasy.hcuge.ch
/www/expasy-top.html). Due to the large size of the spectrin molecule, absorbance
measurements of spectrin solutions were complicated by scattering. In order to
compensate for this effect, the contribution of absorption due to scattering was
estimated by both the absorbance at 320 and 350 nm (where the absence of
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electronic chromophores was presumed) and the dependence of scattering intensity
on wavelength (23). This usually resulted in about a 3 % correction.
Elastase digestion was performed as before (15). Briefly, the peptides, at
approximately 1 mg/ml in 50 mM Tris at pH 8. 7, were incubated with elastase at
20 °C (mass ratio of peptide to elastase was about 1:250), and aliquots were
analyzed by SDS-PAGE at 0.5 h intervals for 2 hand then every hour for the next
five hours.

Stained gels were dried and digitized with a Scanman II scanner

(Logitech; Freemont, CA) at a resolution of 400 dpi. The protein content of
individual bands in each lane was determined by integration of digitized images of
band intensities, using the SigmaGel program (Jandel Scientific Software; San
Raphael, CA). Time constants for the disappearance of each peptide ("tg) were
determined by fitting the initial band intensity (10) and the remaining band intensity
(I), at each time point (t), to a simple exponential decay curve I/10 =exp (-ti\).

Molecular masses of the initial peptides, as well as the degradation products were
measured by comparison to standards of known molecular mass.
FTIR spectra were collected as previously described (14). Briefly, samples
at - 30 mg/ml in 5 mM sodium phosphate buffer at pH 7.4 were used. Spectra were
collected using a BioRad FTS 410 FTIR spectrophotometer and a cell path length
of6 µm. An interferogram with a size of 4,600 points, corresponding to the 400 to
4,000 cm·1 region, was acquired for 1,024 scans. Buffer and atmosphere (for water
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vapor) blanks were subtracted from each sample to yield a flat baseline in the 1, 750
to 2,000 cm·1 region. Center frequencies of the amide I bands were determined by
second derivative maxima.
CD measurements on samples at about 1.5 mM residues (A280 - 0.2) were
obtained with a JASCO 710 CD spectrometer, using a thermostated (water
jacketed) cell with 0.1 cm path length. Under our buffer conditions (PBS), spectra
were limited to wavelengths greater than 190 nm. Spectra were obtained at 0.5 nm
resolution from 190 to 300 nm, using subtraction of a buffer blank to smooth the
baseline. The molar ellipticity at 222 nm, <1> 222 (degree cm2 dmol- 1), was calculated.
In determining a-helical contents for each peptide from CD data, the more
usual deconvolution procedures that yield percentage compositions of a-helix,

P-

sheet, turns and random coil (24, 25) were not used. These methods rely on a basis
set of proteins composed of known percentages of the secondary structural elements
and most accurately predict structures of proteins with similar structural elements.
Proteins containing structures of coiled coils were generally not included in the basis
set. In addition, the specific alignment of the a-helices with respect to each other
in spectrin is not random (being exclusively parallel or antiparallel), a situation that
is known to distort CD spectra (24), further complicating the analysis. Thus, we
followed the method used for dystrophin, which has a structure similar to spectrin,
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by using a value of cl> 222 = -36,000 degree cm2 dmo1· 1 to represent peptides with 100

% a-helical structure (18).
Urea denaturation of the peptides was measured by fluorescence
spectrometry, using a Hitachi F-2000 fluorescence spectrophotometer at 20 °C with
a 1 cm path length cuvette. Samples with A280 - 0.02 in PBS were incubated with
urea at different concentrations (0 - 6 M) and allowed to equilibrate overnight (16 20 h). Using an excitation wavelength of278 nm, emission spectra from 315 to 385
nm for each sample were collected. The values of the mean emission wavelength,

A.mean defined as

~an = ~

I

/~ J

A.· 1 (26, 27), were calculated from values of

intensity at each wavelength A. (IJ for each spectrum and used to monitor unfolding.
This parameter is a more suitable measure of unfolding than either simple intensity
measurements at a particular wavelength (28), or a ratio of intensities at two
wavelengths (29). Since A.mean incorporates the information in the whole emission
spectra, it is less noisy, and more sensitive to changes in any region of the spectra
than those obtained with other generally used methods. The use of this parameter
also eliminates the need to single out any particular wavelength for intensity
measurements. This is important in multi-step transitions, as certain wavelengths
may emphasize one transition over the others and give an incomplete view of the
unfolding transition. Most of the A.mean denaturation data were fit to a singletransition two-state model, in which the free energy change of unfolding (LlG) was
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linearly proportional to urea concentration (U), according to the following equation.
To simplify the fitted equation, AG' was used and was defined as AG/RT.
Amean, U=Amean,O + AA mean(e·AG'.(1-U/[UreaJ...))/{l +e·AG'.(l-U/[UreaJ...)) , where A mean,O is
the A.mean value without urea and Amcan,u is the A.mean value at each urea concentration

U. Parameters to be fitted from the experimental points were AG' 0, [Urea]mid' Amean,o
and AA. mean· Some data clearly showed two transitions, implying the presence of
three states (native, intermediate and denatured states). These data were then fitted
to a three-state model, which was extended from the two-state model.
In order to determine if the samples were indeed at equilibrium, rates at
which peptides were denatured by 4 M urea (a minimal urea concentration that
sufficiently unfolded all of our peptides) were examined. In these experiments, a
200 µL aliquot of protein sample was rapidly added, at 20 °C with stirring, to
1,800 µL of 4.44 M urea in PBS to yield a final urea concentration of 4 M.
Emission spectra were taken as above at intervals, from 1 min to 250 min. The data
were fit to a multi-exponential decay curve. The choice of either single, bi- or
higher exponential was made by examining the
model with the lowest

x values for the fitted curves.
2

The

x value was chosen, and in all cases was a bi-exponential
2

decay,

Fluorescence time constants ( 'tn and 'tn ) were obtained from these curve fits.
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Denaturation by urea was also monitored by CD. In this experiment, peptide
samples with a final A280 - 0.4 were made up to various concentrations of urea in the
range 0 - 6 M and allowed to equilibrate overnight. «1> 222 was measured for each
sample at 20 °C.
Thermal denaturation was examined by scanning the temperature upward
from 5 to 75 °C, at 1 °C/min, and monitoring «1> 222 • The temperature of the
maximum value of d«l> 22/dT for each peptide was reported as Tm.
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RESULTS
All six spectrin peptides were purified to a high degree of purity. For

example, gel scan analysis ofSDS-PAGE ofSpo:52-156, Spo:52-262 and Spo:52-368
(Lanes 2 in Fig 2A, B and C) demonstrated that these peptides were at least 90 %
pure. Occasionally, trace amounts ofGST at-27 k:Da were also detected in peptide
samples. However, most preparations provided samples with about 99 % purity.
Molecular masses as estimated from electrophoretic mobilities were -11 k:Da for the
three peptides containing 105/106 amino acids (Spo:52-156, Spo:157-262 and
Spo:263-368), -29 k:Da for peptides with two domains (Spo:52-262 and Spo:157368), and -37 k:Da for Spo:52-368. N-terminal sequencing of all six peptides
confirmed the identities of the first 2 residues of each construct as GS (left from the
thrombin cleavage site), followed by the appropriate residues of spectrin. TOFMALDI-mass spectral analysis of Spo:52-156, Spo:52-262 and Spo:52-368
demonstrated that the peptide masses were 12.64, 24.86, and 37.05 k:Da,
respectively, and were within 0.4 % of the theoretical masses (12.65, 24.87, and
36.92 k:Da, respectively).
Solution molecular masses obtained from 15 and 90 degree light scattering
data for Spo:52-156, Spo:52-262 and Spo:52-368 in PBS were 10.4, 20.4, and 31.1
kDa, respectively (Fig 1). These results clearly showed that these peptides, at
concentrations of 0.1 - 1 mg/ml in PBS, existed in monomeric form. That these light
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scattering measurements were able to detect oligomers of similar peptides was
shown by measurements of the solution molecular mass of a protein encoding the
first 446 amino acids of the spectrin sequence (Spal-446). This peptide exhibited
substantial amounts of dimer and higher order oligomers, indicated by the arrows
in Fig 1.
Proteolysis of the peptides with elastase showed that they were all resistant
to digestion, but to different extents. Intensities ofthe bands for Spa52-156 (11.3
kDa, Fig 2A), Spa52-262 (28.8 kDa, Fig 2B) and for Spa52-368 (37.2 kDa, Fig
2C) decreased as a function of elastase digestion time.

The first order time

constants (tg) for the disappearance of these bands were 1.1 h for Spa52-156, 2.3
h for Spa52-262 and 3.5 h for Spa52-368. These data showed that Spa52-368
resisted digestion the most, followed by Spa52-262, and finally by Spa52-156. The
other two single-domain peptides (Spal57-262 and Spa263-368) exhibited
digestion patterns (not shown) similar to those of Spa52-156.
With prolonged incubation, multiple-domain peptides (Spa52-262, Spal57368 and Spa52-368) yielded digestion products of about 100 - 130 amino acid
residues (12 - 15 kDa), corresponding to fragments presumably containing a single
sequence motif of 106 amino acids. The enzyme cleavage sites for the N-terminal
portion (residues 1-167) of spectrin were given earlier (15). The specific molecular
masses measured for these products in Spa52-262 samples were 14.5 kDa
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(appeared after 0.5 h incubation, Fig 2B) and 12.9 kDa (Fig 2B, lanes 7-11).
Spa52-368 (37.2 kDa; Fig 2C, lane 2) was first digested to 30.2 and 27.8 kDa
fragments (Fig 2C, lanes 4-11 ), corresponding to fragments containing two
sequence motifs, and then to 14.2 kDa (Fig 2C, lanes 6-11), fragments containing
a single sequence motif In each case, bands near but slightly larger than the
expected size (14.5 and 12.9 kDa bands during the digestion of Spa52-262, when
a single motif of about 11 kDa band was expected; and 30.2 kDa band for Spa52368 with two motifs of about 29 kDa band expected) probably reflects site
preference specificity of elastase. In a previous study, we identified a similar
product as being a whole domain plus the third helix of the previous domain (15).
However, these larger fragments were not as stable as the smaller fragments, and
were converted to the latter products over time. The fact that these products
accumulated, while no products smaller than the expected size accumulated,
emphasizes the intrinsic stability of these fragments.
The implication of these results was that each 105/106 amino-acid-residue
fragment, either as individual peptides (Spa52-156, Spa157-262 or Spa263-368)
or· as components in larger peptides (Spa52-262, Spa157-368 or Spa52-368),
formed compact structures that were resistant to internal proteolysis and thus had
some domain-like properties. However, the individual domain structures in multidomain peptides (Spa52-262, Spa157-368 or Spa52-368) appeared to interact to

117

provide a structure more resistant to proteolytic digestion than in Spa52-156,
Spa157-262 or Spa263-368.
CD spectra of all peptides exhibited characteristics of high a-helical content.
A typical spectrum of Spa52-262 in PBS at 20 °C (Fig 3A, solid line) consisted of
a highly a-helical signature with double minima at 208 and 222 nm. Other peptides
exhibited similar spectra, except with different <1> 222 values (-18.7, -20.5, -18.4, -25.7
and -27.4 x 103 deg cm dmof

for Spa52-156, Spa157-262, Spa263-368,

Spa157-368 and Spa52-368, respectively). These values corresponded to helical
contents of 51 - 57 % for peptides with single domain, 71 - 83 % for peptides with
two domains and 76 % for the peptide with three domains (Table 1). When treated
similarly, the <1> 222 value obtained for intact spectrin dimer corresponded to a 64 %
helical content. This is consistent with a value of 69 % as measured by VCD (14),
or 68 % as measured by CD (30).
The FTIR central frequency of the main component of the amide I band
(assigned to the a-helix of spectrin, see Ref. 14) was about1652 or 1653 cm· 1 for
peptides with single domain, 1650 or 1651 cm· 1 for peptides with two or three
domains (Table 1). The value for spectrin was 1650 cm·1 (14). Although these
values were all indicative of a-helix structure, the frequency shifts reflected changes
in hydrogen bond strength within helices, with lower frequencies corresponding to

stronger or more extensive H-bonding networks (14).
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In summary, both FTIR and CD data revealed that the spectrin peptides
exhibited high helical contents, suggesting that these recombinant peptides were well
folded, presumably as triple helical bundle for each 105/106 amino acid residues.
These results are in good agreement with the elastase digestion results. However,
the FTIR and CD measurements also indicated that peptides with single domain
were slightly less well folded than peptides with multiple domains or intact spectrin.
CD spectra of of our peptides at 75 °C were virtually featureless, implying
that the peptides were extensively denatured from their native a-helical
conformations at this temperature. The spectrum of Spa52-262 is shown as an
example in Fig 3A, dotted line. Thermal denaturation as monitored by CD showed
that Tm for single-domain peptides were 40, 48 and 50°C and for two-domain
peptides were 50 and 56 °C. The Tm value was 54 °C for the three-domain peptide
(Table 1). Thus thermal denaturation results suggested that peptides with singledomain were less stable than peptides with multiple domains. Spectrin denatured
at Tm = 4 7 ° C, indicating that at least portions of this molecule were in fact more
sensitive to thermal stress.
CD spectra of all peptides in the presence of 6 M urea at 20 ° C were also
virtually featureless, again implying that the peptides were extensively denatured
from its native a-helical conformations by urea treatments. The spectrum of a
Spa52-262 sample is shown as example in Fig 3A, dashed line. Analysis of CD
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spectra of all recombinant peptides and of spectrin as a function of urea
concentration revealed that the urea denaturation profiles were well fitted by the
two-state, single-transition model to give the parameter [Urea]mid· The mean values
for [Urea]mid (Fig 3B, Table 1) for single domain peptides were 2.3 M for
Spa52-156, 2.2 M for both Spal57-262 and Spa262-368, but 3.1 - 3.3 M for twodomain peptides and 3.9 M for Spa52-368. The mean value for spectrin samples
was 4.0 M (Fig 3B, Table 1). Again, these values indicated that single domain
peptides (Spa52-156, Spal57-262 and Spa263-368) were the easiest to be
unfolded by urea, followed by two-domain peptides (Spa52-262 and Spal57-368).
The three-domain peptide (Spa52-368) was the most stable peptide with respect to
urea unfolding. It was also interesting to note that the unfolding of the larger
peptides was more cooperative than the unfolding of the smaller peptides (Fig 3B),
suggesting interactions between domains in the larger peptides.
Fluorescence urea denaturation data of all peptides except Spa52-262 (for
example see data for Spa52-156, Spa52-368 and spectrin in Fig 4) were all well
fitted by the two-state, single-transition model used for the CD denaturation
experiments. The mean values for [Urea]mid ranged from 0.04 - 2.5 M for singledomain peptides, 2.8 - 3.2 M for two-domain peptides, but were 3.6 M for Spa52368 and 4.1 M for spectrin samples (Table 1). The wavelength with maximum
intensity (A.maJ of Spa52-368, for example, moved from 345 nm to 351 nm (red
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shifted) in the presence of 6 M urea, indicating that the fluorophores (tryptophan
residues) moved from a relatively hydrophobic, solvent-inaccessible environment to
a more polar, solvent-exposed environment. This is consistent with published work
showing that tryptophan residues in similar spectrin fragments are in a shielded
hydrophobic environment and appear to form a folding nucleation site (31 ). The
general close correlation of the values of [Urea]mid measured by both CD and
fluorescence techniques indicated that the two processes (unfolding of helical
structures monitored by CD, and the release of buried tryptophan residues to more
exposed solvent environment monitored by fluorescence) were generally linked.
Spa52-262 exhibited a unique, second transition at a lower urea
concentration in fluorescence studies (Fig 4). The data were analyzed with threestate model to include an intermediate state. The mean value for [Urea]mid for the
first transition was about 0.4 M. The second transition was at about 3.2 M (Fig 4),
a value similar to those of peptides that exhibited only a single transition. The low
urea transition was most evident in the blue end of the emission spectra. The change
was primarily one of quenching, with only a small red shift evident (A.max moved from
347 to 353 nm). The high urea concentration transition resulted in a larger red shift

(A.max moved from 353 to 362 nm) with a slight intensity increase. These results
show the merit of using A.mean (Fig 4) as the parameter reflecting unfolding. If a
single wavelength were used, in addition to producing noisier data, only one of the
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transitions might be detected without significant contribution of the other. For
example, a transition at urea concentration of about 0.4 M was easily seen when the
fluorescence intensity at 320 run was examined, but there was little indication that
another transition occurred at higher urea concentrations. Conversely, when the
intensity at 370 run was examined, a transition near 3.2 M was observed, with no
sign of the transition at urea concentration less than 1 M.
The possibility that the low urea transition was an artifact of incomplete
equilibration was eliminated by examining the rate at which these peptides reached
equilibrium in the presence of 4 M urea. It was found that the Spcx52-156 samples
reached their final denatured states very rapidly (within 1 min at 20 °C). In other
samples (Spcx52-262, Spcx52-368 and spectrin), the data were fitted best with a biexponential decay, with a fast phase and a slow phase. The fast phase with 't'n <
0.02 h (~ 1 min) was poorly defined due to the paucity of data at this time scale and

will not be further considered. The time constant for the slow phase (-rf2) was 0.6 h
for Spa52-262 and 1.3 h for Spa52-368, and 1.9 h for spectrin. Clearly our
incubation time of 16 - 17 h was sufficient for our samples to reach thermodynamic
equilibrium in the denaturation studies. The additional possibility that these
secondary transitions reflect oligomerization equilibria was considered, since some
of these spectrin recombinant peptides appear to undergo self association (9, 32).
However, the observed solution masses for our peptides clearly showed that they
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existed as monomers in solution under the experimental conditions used for CD and
fluorescence measurements.
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DISCUSSION
Common assumptions made in the study of proteins containing repetitive

sequence motifs, such as spectrin, are that each repetitive sequence motif folds into
a structural domain, and that these domains are similar to each other and constitute
classical independent structural units. Thus, when structures of parent proteins are
difficult to obtain, peptides of a single sequence motif of the parent protein are often
used to study the structure of the parent protein. However, that a polypeptide can
form a stable structure is a necessary, but not sufficient, cause for it to be considered
as an individually folded, independent structural unit. Independence of folding and
stability need to be demonstrated experimentally.

Such demonstrations entail

examining the properties of the individual domains in isolation, which must be
substantially similar to those of the structures when present in the parent protein.

In the case of proteins containing spectrin-like sequence motifs, the hypothesis that
each sequence motif folds into an independent structural unit has been supported by
two main lines of evidence: resistance to proteolysis, which pertains to the first
folding criteria, and spectroscopic (CD and fluorescence) evidence which pertains
to the latter phenomenological criteria.
Proteolytic resistance has been widely used and has been employed to study
fragments containing different repetitive sequences of various spectrins (15, 16), of

actinin (17) and ofdystrophin (18). The basis of this approach is that a polypeptide
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that is a complete domain will be able to fold into a compact structure. Since
proteolytic sensitivity is correlated to the flexibility (33) and accessibility (34) of
peptide structures, these putative domains will be resistant to proteolysis while
intervening regions will be susceptible. In all of the above studies, polypeptides
expressed became resistant to proteolysis only when they spanned a complete
sequence motif and when they started at a specific point within the sequence motif

(i.e., they were expressed in the proper phase). Our earlier work showed that a
properly phased spectrin sequence motif, containing residues 52-156, was resistant
to proteolysis whereas a fragment containing an alternative phasing, containing
residues 49-155, for example, was much less (> 10 fold) resistant to proteolysis
(15).

An additional incomplete repetitive sequence motif on either end of a

complete sequence motif was rapidly digested, showing that while each complete
sequence motif could form a compact structure, fractional sequence motifs could
not.

Gratzer and co-workers expressed fragments of dystrophin (18) and

demonstrated that properly phased single sequence motifs exhibited a high
proportion of a-helix as measured by CD, while improperly phased sequence motifs,
differing by only a few amino acids, exhibited much lower helicity.

These

experiments clearly showed that these single spectrin-like sequence motifs could fold
into a compact structure, which might be true domains. However, one hint that
these structures exhibit some cooperativity comes from the observation that when
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two sequence motifs of actinin are expressed in tandem, they are more resistant to
proteolysis than either of the isolated constituent motifs, a terminal fractional motif,
or improperly phased motifs (17).
We found that fragments containing one (first, second, or third), two (first
two or second and third), and three (first three) sequence motifs of a-spectrin were
all relatively stable to proteolysis, but eventually succumbed to digestion and
produced fragments of about 11-12 kDa, the size of a single sequence motif These
results suggest that, although the single sequence motifs in these multi-motif
peptides form some sort of self-contained and protease-resistant structure, their
structures are not completely independent, with Spa52-156, Spa157-262 and
Spa263-368 being the least resistant to elastase, followed by Spa52-262 and
Spa157-368, and finally by Spa52-368.
Our structural integrity studies indicate a similar stability series. All data,
including the FTIR, CD, and/or fluorescence spectra, indicated that the peptides
with a single domain (Spa52-156, Spa157-262 and Spa263-368) were folded into
compact structures that contained substantial a-helix (about 55 %). However, the
peptides with multi-domains (Spa52-262, Spa157-368 and Spa52-368) exhibited
higher helical contents (about 75 % or more). FTIR results indicated that singledomain peptides exhibited frequency value at 1652-1653 cm·1, slightly shifted from
the values seen for the other peptides (1650 - 1651 cm-1). Since the exact position

126
of this band within the amide I region has been correlated to hydrogen bond
strength, this indicates that the hydrogen bonds in single-domain peptides are slightly
weaker than that in the other multiple-domain peptides, consistent with a slightly
expanded structure.
The amount of denaturant needed to disrupt these structures also increased
along the same stability series, with Spa52-368 being the most stable and
Spa52-156, Spa157-262 and Spa263-368 being the least stable ones.

This

stabilization was also seen kinetically with rates of denaturation being much slower
for the larger peptides, as well as with thermal denaturation, in which the Tm values
measured were greater for the larger peptides. In all measurements involving
denaturation, Spa52-368 was most similar to intact spectrin and the single-domain
peptides least similar.
Thus, our data suggest that the spectrin repetitive sequence motifs are not
classical independent structural domains, but rather are interactive stabilizing substructures. This may have some bearing on the functional properties of spectrin and
in particular to its role in some genetic diseases, such as hereditary elliptocytosis
(HE) and hereditary pyropoikilocytosis (35). These diseases are often associated
with spectrin mutations, which result in reduced levels of spectrin in the membrane
skeleton (36, 37). Erythrocyte membrane integrity relies on a number of interactions
of spectrin with itself and with other membrane proteins, as well as with lipids, but
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interactions especially germane to this study are the head-to-head interactions
between the ap spectrin dimers to form the ( ap) 2 spectrin tetramers. Since the
dimer-dimer interaction is primarily thought to be the result of the complementary
association of sequences in the first 50 residues of a-spectrin with a region at the Cterminus of P-spectrin to form a stable hetero-polypeptide triple a-helical bundle
(38), it is easy to see how mutations at the terminal ends involved in this interaction
may disrupt this process and lead to decreased interaction. Many such mutations are
known and indeed these altered spectrin molecules show impaired self-association
(39). It is less easy to see how mutations distal to regions involved in direct
interaction, and as far as four sequence motifs (> 400 amino acids) away could
disrupt dimer-dimer self association; however such mutations are known. For
instance, a spectrin variant, Alexandria, with a deletion of a histidine at position 469
in the a-spectrin chain, exhibits decreased tetramerization (as measured by
perturbation of the dimer-tetramer equilibrium in 4 ° C extracts of erythrocyte
membranes) (40). Similarly, a HE spectrin variant, Sfax, resulting in the splicing out
of codons 363 to 371 in helix three of the fourth sequence motif(41) also shows
increased levels of spectrin dimers and by inference reduced dimer-dimer
association. The conclusion to be drawn from these unusual spectrin mutations in
HE patients is that mutations distal to the dimer self-association site may have their
effects propagated through the intervening domains to the association site by
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mechanisms that would imply communication and thus cooperativity between the
structural units that are formed by these domains. Thus, clinical observations
corroborate our experimental evidence based on proteolytic and denaturant stability,
implying that the spectrin-like-sequence motif, while forming structures with limited
independence of function, are not truly independent domains.

Our data also

demonstrate that the structural properties of peptides of single sequence motifs
differ from those of spectrin molecules.

There appears to be substantial

communication between structural domains containing these sequence motifs, and

in order to adequately mimic the properties of spectrin several tandem domains must
be considered.
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FOOTNOTES

Spai-j - Human erythroid a-spectrin recombinant peptide composed of residues i

to j; A280 - absorbance at 280 nm; CD - circular dichroism; ~G- free energy change
in unfolding; FTIR - Fourier transform infrared; ~ 222 - CD ellipticity at 222 nm; HE hereditary elliptocytosis; IA - fluorescence intensity at wavelength A;

Amean - mean

emission wavelength; Amax - wavelength with maximum intersity; PBS - 5 mM
phosphate buffer containing 150 mMNaCl at pH 7.4; 'tn - time constant for the fast
phase in urea unfolding (from fluorescence results);

1:12 -

phase in urea unfolding (from fluorescence results);

time constant for the slow
1:8 -

time constant for the

disappearance of peptide by elastase digestion (from gel data); U - urea
concentration; [Urea]mid - mean urea concentrations for transition from native to
denatured state; Tm - temperature of maximum value of 3~ 222/c>T.
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FIGURE LEGENDS

Figure 1

Solution molecular mass distribution of Spa52-156 (solid line),
Spa52-262 (dashed line) and Spa52-368 (dotted line) in PBS,
obtained from light scattering results. These peptides exhibit single
peaks at 10.4, 20.4 and 31.1 kDa, respectively. The concentrations
of the samples in PBS ranged from 0.1 to 1 mg/ml. The molecular
masses are all near the theoretical masses for monomers. The ability
of this technique to discern oligomerization is demonstrated by the
presence of substantial dimer (large arrow) and trimer (small arrow)
populations in another peptide, Spcx 1-446 (dash-dotted line).

Figure 2

SDS-PAGE of elastase digestion products of Spcx52-156 (Panel A),
Spa52-262 (Panel B) and Spa52-368 (Panel C). The first lane in
each gel contained molecular weight standards (43.0, 29.0, 18.4,
14.3 and 6.2 kDa). Subsequent lanes (lanes 2 - 11) contained an
aliquot of each digestion reaction quenched at various times: 0, 0. 5,
1, 1.5, 2, 3, 4, 5, 6 and 7 h. Intensities of the band for Spa52-156
(11.3 kDa, Panel A), for Spa52-262 (28.8 kDa, Panel B) and for
Spa52-368 (37.2 kDa, Panel C) decreased as a function of elastase
digestion time. Spa52-262 eventually yielded fragments at 14.5 and
12.9 kDa, and Spa52-368 yielded fragments at 14.2 kDa. The sizes
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of these fragments were similar to the size of Spa52-156. Spa52368 also yielded intermediate fragments at 30.2 and 27.8 kDa,
similar in size to Spa52-262. The band at 27 kDa (Panel B, under
the Spa52-262 band) exhibited constant intensity throughout the
incubation, and was assumed to be that of contaminating GST.
Figure 3

CD Spectra and CD Monitored Denaturation.

A. Typical CD

Spectrum of Spa52-262. The CD spectrum of Spa52-262 was
recorded in PBS at 20°C (solid line), PBS at 75 °C (dotted line),
and PBS plus 6 M urea (dashed line). The highly a-helical signature
in Spa52-262 spectrum in PBS gave way to a virtually featureless
spectrum when the peptide was denatured by either temperature or
urea. Other peptides exhibited substantially similar spectra, except
with different maximal signal intensities.

See text for detailed

discussions. B. Urea mediated denaturation was monitored by CD

(<1> 222

)

for Spa52-156 (square •), Spa52-262 (triangle .6.),

Spa52-368 (diamond+), and spectrin (circle 0). All peptides show
a single transition.
Figure 4

Fluorescence Monitored Denaturation. Fluorescence studies of urea
denaturation of Spa52-l 56, Spa52-262, Spa52-368 and spectrin
samples.

Urea mediated denaturation was monitored by
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fluorescence for Spa.52-156 (square•), Spa.52-262 (triangle•),
Spa.52-368 (diamond +), and spectrin (circle 0). The mean
emission wavelength )..mean at each urea concentration was used. All
proteins show a red shift upon denaturation. Spa.52-156 started
from a longer wavelength ( Amean - 3 50 nm) than the others, (Amean 344 nm). This may indicate a lesser degree of compaction in this
peptide.

Spa.52-262 shows two transitions, one at high urea

concentration to a denatured state, and one at low urea
concentration between a seemingly completely folded state, with a

A.mean - 345 nm, and an incompletely folded intermediate with a A.mean
- 349 nm, similar to that of native Spa.52-156.
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TABLES

Table 1

Structural Properties Derived from Various Spectroscopic and
Proteolytic Results of Spectrin Peptides and of Spectrin Molecules
in PBS

CD
Fluorescence
Protein Amide I (cm· 1t a-helix (%)c

Irn-CCt

[Urea]mi~

UJmUnm!M)

Spo:52-156

1652.7

52

40

2.3

2.5

Spa157-262

1651.5

57

50

2.2

0.04

Spo:263-368

1651.9

51

48

2.2

2.0

Spo:52-262

1650.2

83

50

3.3

3.2

Spo:157-368

1650.9

71

56

3.1

2.8

Spo:52-368

1651.3

76

54

3.9

3.6

Spectrin

1649.9

64

47

4.0

4.1

3Generally, the values presented in this Table were mean values of 3-4 experimental
runs. Maximum standard deviations were given below. bAmide I frequency values
from FTIR measurements provide information on hydrogen bond strength in helices.
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Standard deviations were less than 0.3 cm·1. ca-helical contents(%) were calculated
from cl> 222 values of CD spectra at 20 °C, using the value 36,000 degree cm2 dmo1· 1
for 100 % helix. The calculations of this and other parameters in this table were
discussed in detail in the Experimental Procedures section. Standard deviations were
less than 5 %.

ctrm was the temperature of maximum value of l>ct> 221/ 5T. Standard

deviations were less than 1°C. e[Urea]mid was mean urea concentrations for the
transition to the denatured state obtained from CD or fluorescence results. Standard
deviations were less than 0.2 M.
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